Transmission Barriers for Bovine, Ovine, and Human
http://www.100md.com
病菌学杂志 2005年第9期
Institute for Neurodegenerative Diseases, and Departments of Neurology Pathology
Biochemistry and Biophysics, University of California, San Francisco, California
ABSTRACT
Transgenic (Tg) mice expressing full-length bovine prion protein (BoPrP) serially propagate bovine spongiform encephalopathy (BSE) prions without posing a transmission barrier. These mice also posed no transmission barrier for Suffolk sheep scrapie prions, suggesting that cattle may be highly susceptible to some sheep scrapie strains. Tg(BoPrP) mice were also found to be susceptible to prions from humans with variant Creutzfeldt-Jakob disease (CJD); on second passage in Tg(BoPrP) mice, the incubation times shortened by 30 to 40 days. In contrast, Tg(BoPrP) mice were not susceptible to sporadic, familial, or iatrogenic CJD prions. While the conformational stabilities of bovine-derived and Tg(BoPrP)-passaged BSE prions were similar, the stability of sheep scrapie prions was higher than that found for the BSE prions but lower if the scrapie prions were passaged in Tg(BoPrP) mice. Our findings suggest that BSE prions did not arise from a sheep scrapie strain like the one described here; rather, BSE prions may have arisen spontaneously in a cow or by passage of a scrapie strain that maintains its stability upon passage in cattle. It may be possible to distinguish BSE prions from scrapie strains in sheep by combining conformational stability studies with studies using novel Tg mice expressing a chimeric mouse-BoPrP gene. Single-amino-acid substitutions in chimeric PrP transgenes produced profound changes in incubation times that allowed us to distinguish prions causing BSE from those causing scrapie.
INTRODUCTION
Prion diseases are fatal degenerative disorders of the central nervous system (CNS). The pathogenesis of prion diseases involves conversion of the host-encoded prion protein (PrP), denoted PrPC, into an insoluble isoform (PrPSc) that accumulates in the CNS. PrPSc is the only known component of the infectious pathogen (43). PrPC undergoes a profound conformational change as PrPSc is formed; this structural transition is characterized by an increase in ?-sheet content and the disappearance of several surface epitopes (12, 33, 37, 41, 46, 49, 51, 67). Moreover, this conformational change is the fundamental event in prion replication.
To distinguish PrPSc from PrPC, limited digestion with proteases is commonly employed, during which PrPC is readily digested and PrPSc is N-terminally truncated to form PrP 27-30 (4, 45, 46). Concerned that proteolytic digestion was destroying a significant portion of PrPSc, one of us (S.B.P.) developed the conformation-dependent immunoassay (CDI) for measuring PrPSc. The CDI uses antibodies directed to epitopes that are exposed in PrPC but buried in native PrPSc (52). The buried epitope in PrPSc becomes exposed upon denaturation, and the difference in immunoreactivities between the denatured sample and the native sample is equal to PrPSc. From studies with the CDI, we learned that a minority of PrPSc molecules are protease resistant and that we had underestimated the level of PrPSc b yas much as 90% in some instances. These results indicated that PrPSc adopts both protease-resistant (r) and -sensitive (s) conformations.
Bovine spongiform encephalopathy (BSE) (26) of cattle and chronic wasting disease of deer and elk (68) were recognized as new prion diseases in the 1980s. It has been estimated that 750,000 cattle infected with BSE prions were slaughtered for human consumption in Great Britain during a period spanning from 1980 to 1996 (1, 17). It now seems clear that during this period, the disease passed to humans through the consumption of contaminated beef products, leading to the emergence of a new, variant form of Creutzfeldt-Jakob disease (vCJD). While epidemiological studies (65, 66) and prion strain typing experiments (7, 15, 24) suggested that vCJD is caused by the transmission of BSE prions to humans, compelling evidence arguing for an etiologic link between BSE and vCJD came from the demonstration that human vCJD prions precisely recapitulate the properties of bovine BSE prions following transmission to transgenic (Tg) mice expressing bovine prion protein (BoPrP) (58).
Although it is clear that vCJD in humans is caused by BSE prions, it is unknown what proportion of those exposed to BSE prions will eventually develop vCJD. Moreover, it is not known whether consumption of chronic wasting disease-tainted venison poses a risk to humans. Although prion diseases are not generally communicable, experimental transmission of prion diseases between hosts of the same mammalian species is typically highly efficient, with a uniform and consistent incubation period. In contrast, prion transmission between animals of different species often fails to cause disease even after prolonged incubation periods. This comparative resistance to infection, as seen in the first passage to a new species, has been termed the species barrier (38).
Studies with Tg mice (47, 48, 54, 55, 57, 62), mice with deficient endogenous PrP gene (Prnp0/0) expression (9, 44), and homologous recombinants (3, 34) established the role of the PrP sequence in modulating susceptibility to foreign prions. However, the work presented here and elsewhere (29) demonstrate that the strain of prion may eliminate the transmission barrier imposed by sequence differences and vice versa. In some cases, a chimeric or mutated gene may be able to confer greater susceptibility to prions, provided that the new PrP sequence is compatible with the prion strain in the inoculum.
Tg(BoPrP) mice are highly susceptible to BSE prions, and the infected animals faithfully recapitulate many of the features of BSE in cattle (57). These same mice are also highly susceptible to both vCJD and natural sheep scrapie prions (58). We developed a new line of Tg mice homozygous for the BoPrP transgene, and this facilitated the breeding of large numbers of animals required for an endpoint titration study (53). The titers obtained, which were equal to or greater than 107 infectious units per gram of tissue, indicated that these Tg mice are 10-fold more susceptible than cattle and 104-fold more sensitive than wild-type mice to BSE prions (53). We presume that the heightened sensitivity of these Tg mice to BSE prions compared to cattle is a consequence of the overexpression of BoPrP (11, 47, 63). Overexpression of PrP in mouse neuroblastoma cells also appears to increase the susceptibility of these cells to infection with mouse prion strains (36).
In the study reported here, we demonstrate that some isolates of sheep scrapie prions transmit very efficiently to Tg(BoPrP) mice, with no evidence of a prion transmission barrier. In contrast, vCJD prions transmit less efficiently, with an 30-day change in incubation period from first to second passage. Tg(BoPrP) mice were resistant to all other human prions tested. We next created a series of chimeric mouse-BoPrP transgenes and showed that they confer various degrees of susceptibility to BSE, vCJD, and scrapie prions. One line of Tg mice appear highly susceptible to BSE prions but not to scrapie prions and may be suitable for selectively identifying BSE strains in sheep.
MATERIALS AND METHODS
Chimeric transgenes and production of transgenic mice. Tg(BoPrP)4125 and Tg(BoPrP+/+)4092 mice have been described previously (53, 57, 58). The Bo3M open reading frame (ORF) was created by replacing the N-terminal coding sequence of the MBo2M chimera (58) with the corresponding sequence from the native BoPrP ORF cassette (58). This exchange of sequences exploited the presence of a single PstI restriction enzyme cleavage site that cleaves within the homologous BoPrP-derived sequences. Additional chimeric PrP transgenes were created by replacing regions of the Bo3MPrP ORF with synthetic double-stranded DNA oligonucleotides to create a series of chimeras (Fig. 1). Complete sequences of the chimeric ORF constructs in GenBank-compatible format were determined (data not shown). Plasmid manipulations were prototyped, and sequences were archived by using Vector NTI software (Informax, Inc., Frederick, Md.).
Prion isolates and transmission studies. BSE isolates from samples GJ248/85, SE1809/11, 97/1612, 97/1997, and PG31/90 were obtained from John Wilesmith at the Central Veterinary Laboratory, Weybridge, United Kingdom. Brain samples from vCJD cases RU96/02, RU96/07, RU96/70, RU96/80, and RU96/110 were obtained from Robert Will and James Ironside at the United Kingdom National CJD Surveillance Unit. Sheep scrapie isolates Oreo, T97-1104, no. 15, no. 139, and no. 340 have been described elsewhere (58, 64), and all are derived from Suffolk sheep with the ARQ genotype. Tg(BoPrP)-passaged BSE, vCJD, and scrapie isolates were produced in this laboratory and have been described in previous publications (53, 57, 58). Transmissions of the BSE, vCJD, and scrapie isolates to Tg mice were performed as previously described (57). Brain samples used for transmission studies are listed in the figure legends. Brain homogenates were prepared by repeated extrusion through syringe needles of successively smaller sizes, from 22 to 18 gauge. Mice were inoculated with 30 μl of a 1% homogenate (wt/vol) in sterile phosphate-buffered saline without Ca2+ or Mg2+ by using a 27-gauge, disposable hypodermic needle inserted into the right parietal lobe. Following inoculation, the status of the mice was monitored daily while the neurologic status was assessed three times per week. Clinical diagnosis was performed as previously described (11, 55).
Neuropathology. Brains were removed rapidly from animals and either perfusion fixed in 10% buffered formalin or snap-frozen. The brains were embedded in paraffin, and histological sections were stained with hematoxylin and eosin for evaluation of vacuolar (spongiform) degeneration. Vacuolation scores, which are semiquantitative estimates of a brain region occupied by vacuoles (10), were determined by a single rater (S.J.D.). Immunohistochemical localization of PrPSc on formalin-fixed, paraffin-embedded tissue sections was determined by the formic acid-hydrated autoclaving method (35). Sections of formalin-fixed, paraffin-embedded tissue on glass slides were immersed in undiluted formic acid for 2 min followed by autoclaving in 1.3 mM HCl in distilled H2O for 10 min at 121°C. Sections were then incubated overnight at 4°C with the rabbit BoPrP-specific 9095 antiserum (57). After rinsing, the sections were incubated for 30 min at room temperature with biotinylated anti-rabbit antiserum (Vector Laboratories, Burlingame, Calif.) diluted 1:100 in 5% nonfat milk. Following rinses, color was developed with diaminobenzidine.
Preparation of brain homogenates and conformational stability assays. Aliquots of 1% (wt/vol) brain homogenates were added to an equal volume of stock solutions containing increasing concentrations of GdnHCl, chosen to produce the range of final concentrations of GdnHCl indicated in the figure legends. GdnHCl stock solutions were prepared from an 8 M solution (Pierce, Rockford, Ill.) diluted in water. Following 1 h of incubation at room temperature, all samples were diluted with Tris-buffered saline containing 2% Sarkosyl to a final concentration of 0.4 M GdnHCl. Proteinase K was added in a ratio of 1:500, proteinase K-protein (wt/wt), and digested for 1 h at 37°C. The reaction was stopped with 2 mM phenylmethylsulfonyl fluoride. Protease-resistant, insoluble proteins were collected by centrifugation at 50,000 x g for 1 h at 4°C. Pellets were resuspended in lysis buffer (10 mM Tris-Cl [pH 8.0], 0.15 M NaCl, 0.5% NP-40 [wt/vol], 0.5% sodium deoxycholate [wt/vol]), then an equal volume of 2x sodium dodecyl sulfate sample buffer (30) was added, and the mixture was boiled for 3 min prior to electrophoresis. Sodium dodecyl sulfate gel electrophoresis and Western blotting were performed as previously described (57, 58). PrP was detected by using the humanized clone P recombinant antibody (53) and developed by using the enhanced chemiluminescence detection system (Amersham Biosciences, Piscataway, N.J.) as previously described (58).
RESULTS
Susceptibility of Tg(BoPrP) mice to BSE prions. In earlier studies, we presented evidence that transgene-directed expression of BoPrP in Prnp0/0 mice conferred susceptibility to BSE prions (57, 58). Originally, we reported the development of two Tg lines, Tg(BoPrP)4125 and Tg(BoPrP)4092 (57, 58). Of the two, the Tg(BoPrP)4125 line, consistently yielded shorter incubation periods with BSE inocula, a result we attribute to the 2-fold higher level of BoPrP expression, as expected from previous studies on the relationship between the level of PrP expression and the length of the incubation period (10, 47).
Tg(BoPrP)4125 mice were inoculated with multiple isolates containing BSE prions, derived from both infected cattle and Tg(BoPrP) mice (Fig. 2). In these mice, the average incubation period of BSE prions derived from infected cows (240 days) is not significantly different from that obtained with prions derived from BSE-infected Tg(BoPrP) mouse brain (Fig. 2A). Furthermore, when the number of surviving animals was plotted against the incubation period, the curves obtained were superimposable (Fig. 2A). The neuropathologic changes caused by bovine-derived and Tg(BoPrP) mouse-passaged BSE inocula were also indistinguishable (58). By all available criteria, BSE prions were unchanged by serial passage in Tg(BoPrP) mice. This result contrasts with corresponding studies with non-Tg mice (7, 31, 32), in which a change in incubation period from >300 to 150 days was typically observed from the first to second passage. Recent evidence suggests that both the physical properties and pathogenicity of a prion strain may change dramatically when a change in incubation period is observed from first to second passage (40).
Breeding large numbers of Tg(BoPrP+/0)4125 and Tg(BoPrP+/0)4092 mice is hampered by the need to screen all progeny for the presence of the transgene because the mice are hemizygous for the BoPrP transgene. In an effort to establish a mouse model better suited for large-scale bioassays of BSE prions, we attempted to breed both of these lines to homozygosity for the BoPrP transgene array. We were not successful with the Tg(BoPrP+/0)4125 line, presumably because of a deleterious insertion site, but were able to establish a line from Tg(BoPrP+/0)4092 that is homozygous for the transgene (53). We have already reported that these new Tg(BoPrP+/+)4092 mice are up to 10x more sensitive to BSE prions than cattle when used for endpoint titration (53). When Tg(BoPrP+/+)4092 mice were challenged with BSE prions from infected cow brain and from infected Tg(BoPrP) mouse brain, we observed incubation periods of 244 and 247 days, respectively (Fig. 2B), similar to incubation periods for Tg(BoPrP+/0)4125 mice (Fig. 2A).
Susceptibility of Tg(BoPrP) mice to human CJD prions. Expression of the BoPrP transgene conferred susceptibility to vCJD prions (58): incubation periods and characteristic neuropathologic features of Tg(BoPrP) mice infected with vCJD prions closely resembled those found in Tg(BoPrP) mice inoculated with BSE prions. Having performed additional studies resulting in a much larger sample size, it is now evident that the average incubation period (270 days) of Tg(BoPrP)4125 mice infected with vCJD prions (Fig. 2C) is 30 days longer than the 240-day average obtained with the same mice infected with BSE prions from cow brain (Fig. 2A). Although the incubation period for BSE prions did not change upon serial transmission (Fig. 2A), a shortening of incubation period was observed when brains taken from vCJD-infected Tg(BoPrP) mice were retransmitted to Tg(BoPrP+/0)4125 mice (Fig. 2C). In Tg(BoPrP+/0)4125 mice, we found that the incubation period of Tg(BoPrP)-passaged vCJD prions (224 days) was slightly shorter than that obtained with either prions from a BSE-infected cow (240 days) or from BSE-infected Tg(BoPrP) mice (236 days). However, this shortening is probably not significant and may be a reflection of a much smaller sample size in this data set (Fig. 2A and C). When Tg(BoPrP+/+)4092 mice were challenged with prions from vCJD-infected human brain and vCJD-infected Tg(BoPrP) mouse brain, we observed incubation periods of 274 and 240 days, respectively (Fig. 2D), consistent with the results obtained with Tg(BoPrP+/0)4125 mice (Fig. 2C). Whether these changes result from a transmission barrier or a difference in the relative titer of prions in the inoculum is currently unknown.
The finding that Tg(BoPrP) mice appear relatively susceptible to human vCJD prions prompted us to test whether they were equally susceptible to other known human prion isolates. Neither Tg(BoPrP+/0)4125 nor Tg(BoPrP+/+)4092 mice displayed any significant sensitivity to multiple isolates of sporadic CJD (21, 62), familial CJD bearing the E200K mutation (13, 22, 27, 59), or iatrogenic CJD (8) (Table 1). These data clearly demonstrate that susceptibility of Tg(BoPrP) mice to human prions is highly strain dependent. A slight difference in incubation periods was observed when Tg(BoPrP)4125 mice were inoculated with vCJD prions (Tables 1 and 2). The difference was slightly greater than expected from the standard errors, but we do not know the cause for this observation. Whether the inocula differ slightly in titer because different portions of the same brain were used to prepare homogenates for inoculation, and this is reflected in different incubation times, remains to be established.
Sensitivity of Tg(BoPrP) mice to challenge with sheep scrapie prions. In an earlier report, we found that the BoPrP transgene conferred susceptibility to 5 sheep scrapie isolates tested, which were all of the ARQ genotype (58). Compiling all of the available data for transmission of sheep scrapie prions in Tg(BoPrP+/0)4125 mice (Fig. 2E), we found that the average incubation period was 225 days, shorter than the duration for BSE prions (Fig. 2A and C), and 100% of inoculated animals developed disease. Although 80% of the infectedTg(BoPrP+/0)4125 mice exhibited symptoms of disease at 200 days, a plot of the data displayed a notable shoulder at 250 to 300 days. Because most of the animals within this group were originally challenged with a single scrapie sample (data not shown), it is possible that these longer incubation periods are indicative of a different scrapie strain. We do not have serial passage data available for the Tg(BoPrP+/0)4125 line.
We challenged Tg(BoPrP+/+)4092 mice with multiple inocula, including both sheep scrapie prions and Tg(BoPrP) mouse-passaged scrapie prions (Fig. 2F). Tg(BoPrP+/+)4092 mice exhibited an abbreviated incubation time (212 days) following inoculation with scrapie prions isolated from Suffolk sheep (Fig. 2F). It is notable that the incubation period of sheep scrapie is 20 to 30 days shorter than is routinely observed with BSE inocula in both Tg(BoPrP) lines (Fig. 2A, B, D, and E). Significantly, the incubation periods obtained withTg(BoPrP+/+)4092 mice inoculated with Tg(BoPrP)-passaged scrapie prions were essentially identical (216 days) to those observed after inoculation with native scrapie prions (Fig. 2F). We conclude that Tg(BoPrP) mice present no detectable transmission barrier to at least some strains of sheep scrapie prions; moreover, Tg(BoPrP) mice are slightly more susceptible to scrapie prions than to BSE prions.
Molecular properties of Tg(BoPrP)-passaged scrapie prions and BSE prions. To distinguish among different prion strains, we developed a method to characterize prion strains biochemically by assessing the relative conformational stability of PrPSc (39, 40). To compare the relative conformational stabilities of Tg(BoPrP)-passaged BSE and scrapie prions, we employed a variation of this technique. Samples of brain homogenates obtained from BSE- or scrapie-infected Tg(BoPrP) mice were exposed to increasing concentrations of GdnHCl, digested with protease to hydrolyze denatured PrP, and subjected to electrophoresis and Western blotting to detect protease-resistant fragments (Fig. 3A). When PrP band intensities were assessed by densitometric analysis, we were able to determine an approximate [GdnHCl]1/2 value, the concentration at which half of PrPSc in the sample is denatured (39, 40) for each of the Tg (BoPrP) mouse-passaged isolates (Fig. 3B). Tg(BoPrP) mouse-passaged BSE prions displayed a higher relative conformational stability (mean [GdnHCl]1/2 value of 2.8 M) than Tg(BoPrP) mouse-passaged scrapie prions ([GdnHCl]1/2 value of 2.3 M) (Fig. 3A and B).
These initial data allowed us to develop a simple procedure for biochemical strain typing based on the resistance of PrPSc to denaturation after exposure to specific concentrations of GdnHCl. For discriminating BSE and scrapie prions, we opted to compare the relative resistance to denaturation with 0, 2.8, and 3.0 M GdnHCl (Fig. 3C to F). As expected from our transmission studies, the relative susceptibilities of BSE prions derived from bovine brain (Fig. 3C) and Tg(BoPrP) mouse brain (Fig. 3E) appeared similar, with a nearly identical proportion of PrPSc surviving denaturation with 3.0 M GdnHCl. With 2.8 M GdnHCl, PrPSc derived from bovine brain appeared to be slightly more resistant to denaturation than PrPSc derived from mouse brain (Fig. 3C and E). Consistent with the data shown in Fig. 3A, we found that scrapie prions passaged in Tg(BoPrP) mice were much more susceptible to GdnHCl denaturation than BSE prions from either cattle or infected Tg(BoPrP) mice. Only a small PrPSc fraction survived exposure to 2.8 M GdnHCl, and almost all PrPSc was denatured after treatment with 3.0 M GdnHCl. However, we were very surprised to find that scrapie prions from ovine brain appeared highly resistant to denaturation with 3.0 M GdnHCl (Fig. 3D). Although the sheep scrapie samples used for conformational stability studies and the inocula for Tg(BoPrP) mice were all from U.S. Suffolk sheep, insufficient amounts of sheep brain prevented us from performing conformational stability studies on matched pairs. Thus, this condition must temper our conclusions.
Chimeric PrP transgenes. We were surprised to find that Tg(BoPrP) mice are highly susceptible to sheep scrapie prions in the brains of asymptomatic U.S. Suffolk sheep and that these mice posed no transmission barrier to sheep prions. Because of heightened concerns that BSE prions may have been passed to the sheep population via contaminated feed, we sought to devise a transgenic mouse that could be used to discriminate BSE prions in sheep from scrapie prions in sheep, even if the BSE strain was present in a mixture of one or more scrapie prion strains. A chimeric PrP transgene, termed MH2M, comprised of sequences derived from Syrian hamster PrP (SHaPrP) fused to N- and C-terminal sequences from mouse (Mo) PrP (56), was shown to exhibit a transmission barrier when challenged with two different SHa prion strains (40). Tg(MH2M) mice showed no transmission barrier when challenged with the SHa drowsy strain, but transmission of the SHa Sc237 strain was prolonged on the first passage compared to subsequent transmission (40). These results suggested that it may be possible to construct an analogous chimeric mouse-BoPrP transgene with the ability to confer a high degree of susceptibility to BSE prions while retaining relative resistance to infection with most strains of sheep scrapie. However, we had previously created Tg mice expressing a chimeric construct analogous to MH2M, designated MBo2M and differing only in that it contained BoPrP instead of SHaPrP sequences (57). Tg(MBo2M) mice were resistant to infection with BSE prions, leading us to conclude that a C-terminal epitope controls susceptibility to BSE (57). We therefore elected to create a series of new mouse-BoPrP chimeric transgenes, with the goal of furthering our understanding of the relationship between PrP sequence and susceptibility.
In creating a series of transgenes, we used variations of the Bo3M construct (Fig. 1), which is comprised of the N-terminal region of BoPrP fused to the C terminus of MoPrP. The C-terminal MoPrP subregion is identical to that in MBo2M. We next identified five residues in Bo3M PrP that lie within the three-helical C-terminal folded domain of PrPC and that differ between BoPrP and MoPrP (Fig. 1). The residues are at positions 166, 195, 197, 214, and 226 and correspond to residues 154, 183, 185, 202, and 214, respectively, in MoPrP. We then substituted each of these residues in Bo3M with its corresponding residue in either BoPrP or MoPrP and named the resulting transgenes by the amino acid residues present at these five locations (Fig. 1). Tg mouse lines expressing each of the chimeric PrPs were established in a Prnp0/0 background, expanded, and then inoculated with BSE, scrapie, or vCJD prions (Table 2). Wherever possible, we selected lines that showed similar levels of expression of chimeric PrPC. When tested with BoPrP-specific antisera, most were found to express 8 to 16 times the amount of BoPrPC found in brains of control cattle. Whereas most lines fell into this category, the Tg(Bo3M,HVEII)7177 line had a higher level of expression (16 to 32 times).
We were surprised to find that relatively small changes in the sequence could cause dramatic differences in relative susceptibility to the three different inocula used. The Bo3M(HVEII) chimera represents BoPrP up to and including residue 226 fused to the C terminus of MoPrP. It therefore comprises the N terminus, helices A and B from BoPrP, and a hybrid helix C comprising BoPrP sequence but with Arg substituted for Lys at residue 231, as found in MoPrP. All remaining C-terminal sequences including the GPI anchor signal sequence are derived from MoPrP. The Tg(Bo3M,HVEII)7187 line showed incubation periods similar to those of Tg(BoPrP)4125 mice when inoculated with BSE prions (235 days) and vCJD prions (273 days), reproducing the characteristic 35- to 40-day difference in incubation period between these two inocula observed in Tg(BoPrP) mice (Table 2). However, we found that Tg(Bo3M,HVEII) mice exhibited a longer incubation period (317 days) than Tg(BoPrP)4125 mice (225 days) after inoculation with sheep scrapie prions (Table 2). Another line, Tg(Bo3M,HVEII)7177, harboring this construct but with a slightly higher level of chimeric PrP expression, gave similar results but showed longer incubation periods with BSE and vCJD prions and a slightly shorter incubation period with scrapie prions (Table 2). It is interesting that despite the high level of expression, this line showed slightly longer incubation periods for 2 of the 3 inocula than the Bo3M(HVEII)7187 line, which had the same transgene but expressed approximately half the amount of PrPC (Table 2). These data show that transmissions between hosts encoding PrPC of different sequences do not necessarily exhibit an inverse relationship between PrPC expression and incubation period with all inocula.
We obtained dramatically different results with the Bo3M(HVEIV) chimera, a construct that is identical to Bo3M(HVEII), except Ile was changed to Val at residue 226, as found in MoPrP. Of the three residues within helix C of Bo3M(HVEII) that differ between BoPrP and MoPrP, two are identical to MoPrP. The third residue, position 214 at the beginning of helix C, is Ile, as found in BoPrP; the corresponding residue in MoPrP is Val at position 202. Tg(Bo3M,HVEIV)14926 mice were resistant to all three inocula, with no animals showing clinical signs at >550 days postinfection. Susceptibility to prion infection was partially restored by replacing an internal region of BoPrP corresponding to the region between helices A and B with corresponding sequences from MoPrP, resulting in the Bo3M(YIQIV) construct. The Tg(Bo3M,YIQIV)10677 line was susceptible to all three inocula but exhibited prolonged incubation periods (Table 2). An additional substitution of Val for Ile at residue 214 (in helix C) produced the Bo3M(YIQVV) chimera (Fig. 1), which harbors the N terminus of BoPrP, including helix A, fused to the two C-terminal helices of MoPrP. The Tg(Bo3M,YIQVV)12138 line produced yet another susceptibility profile, showing shorter incubation periods with vCJD prions than BSE prions but displaying complete resistance to scrapie prions.
Bo3M(YIQII) chimeric transgenes. The foregoing results demonstrate how minute differences in the sequence of PrP can dramatically alter susceptibility to foreign prions. We became particularly interested in results we obtained with the Bo3M(YIQII) chimera (Table 2). The Tg(Bo3M,YIQII)23953 line exhibited a short (232 days) incubation period after inoculation with BSE prions comparable to our Tg(BoPrP) and Tg(Bo3M,HVEII) mice (Table 2). The Tg(Bo3M,YIQII)23953 line also gave a slightly shorter incubation period (255 days) after inoculation with vCJD prions. However, it appeared relatively resistant to scrapie prions, with an incubation period of 350 days. Such a susceptibility profile may be useful in distinguishing scrapie prions from BSE prions in affected sheep.
To characterize these Tg mice further, we performed a serial transmission study (Fig. 4). We found that BSE prions from infected Tg(Bo3M,YIQII) mice gave even shorter incubation periods (170 days) than BSE prions derived from cattle (232 days), whereas only a slight shift in incubation period (from 347 to 313 days) was observed between scrapie prions from sheep and from Tg(Bo3M,YIQII) mice, respectively. We interpret this to mean that there is a smaller strain barrier for transmission of scrapie prions to these mice compared to BSE prions.
Neuropathology in Tg(BoPrP) and Tg(Bo3M,YIQII) mice. Based on the foregoing data, we performed a detailed comparison of the neurohistopathologic changes caused by BSE, vCJD, and scrapie prions during serial passaging in Tg(BoPrP+/+)4092 (Fig. 5) and Tg(Bo3M,YIQII)23953 mice (Fig. 6). Four relevant findings were made: (i) the neuropathologic changes caused by bovine-derived BSE and human-derived vCJD prions were similar in both Tg mouse lines and were significantly different than those caused by sheep-derived scrapie prions; (ii) these similarities and differences were maintained during the second passage; (iii) large aggregates of PrP amyloid plaques were induced by BSE and vCJD prions but not by scrapie prions; (iv) PrP amyloid plaques were exceptionally large in Tg(Bo3M,YIQII)23953 mice infected with BSE and vCJD prions.
Scrapie, BSE, and vCJD prions could be distinguished by the distribution of vacuolation in the gray matter neuropil. Scrapie was characterized by mild to moderate degrees of vacuolation in multiple cerebral hemisphere and brainstem regions, whereas vacuolation in BSE and vCJD prions was confined largely to the raphe nuclei of the brainstem and to the habenula (Fig. 5 M to R and 6B). In Tg(BoPrP+/+)4092 mice, vacuolation of the brainstem caused by BSE and vCJD prions was largely confined to the raphe nuclei in the midline of the tegmentum (Fig. 5C and D). In contrast, scrapie-associated vacuolation was found throughout the brainstem tegmentum. In Tg(Bo3M,YIQII)23953 mice, BSE prions caused vacuolation throughout the brainstem tegmentum, similar to scrapie prions. Because we have reviewed only one vCJD primary transmission (Fig. 6E and F), we remain tentative about the pattern of vacuolation in Tg(Bo3M,YIQII)23953 mice.
Cattle-derived BSE and human-derived vCJD prions induced deposition of large amounts of PrP amyloid beneath the corpus callosum and ependyma of the rostral half of the cerebral hemispheres in both Tg(BoPrP+/+)4092 and Tg(Bo3M,YIQII)23953 mice (Fig. 5A and E; Fig. 6A and E). Mature amyloid was not found in other brain regions. Upon second passage, similar-sized aggregates of PrP amyloid developed in the same rostral cerebral hemisphere locations (Fig. 5B and F; Fig. 6B). The individual plaques forming these aggregates bound Congo red dye, which showed green-gold birefringence in polarized light, verifying that they are amyloid (data not shown). The plaques varied in size from 10 to 100 μm in diameter (Fig. 6F). The amyloid aggregates were associated with vacuoles and therefore resemble the florid plaques that are characteristic of vCJD in humans (66) (Fig. 6F). The subcallosal amyloid aggregates in Tg(BoPrP+/+)4092 and Tg(Bo3M,YIQII)23953 mice differed in size. Aggregates were relatively small in the former group, whereas they were massive in the latter group, in which they extended continuously as much as 2 mm in a single coronal section. In contrast to BSE and vCJD prions, no amyloid plaques were formed by scrapie prions upon the first or second passage (Fig. 5I and J).
In addition to mature amyloid plaques, primitive plaque-like deposits of PrPSc arranged singly or in aggregates were also formed by BSE and vCJD prions in both the primary and secondary passages in both Tg mouse lines (Fig. 5C, D, G, and H). These deposits were associated with vacuoles in the gray matter neuropil. In contrast, scrapie prions were associated with small, punctate deposits of PrPSc in association with neuropil vacuolation (Fig. 5K and L).
DISCUSSION
Studies of prion transmission barriers are important in elucidating the fundamental mechanisms of prion replication and critical with respect to the safety of the human food supply. In extreme cases, the host may be incapable of supporting propagation of prions from another species; rabbits appear to be resistant to all prion inocula derived from other species (2, 20) and may present such a bona fide species barrier. More typically, however, a relative difference in susceptibility is manifest by a shortening of the incubation period observed when the first passage is compared to the second and subsequent passages. In recent years, several groups (23, 25, 60) have recognized the need to adopt the more generic term transmission barrier to refer to this difference in susceptibility as defined by a difference in incubation period following transmission to a different species or strain of transgenic animal.
As we have shown, in some cases, a transmission barrier may be evident with certain strains but not others, so we introduce the term strain transmission barrier, or simply strain barrier, to denote this. We propose that the majority of the so-called species barriers observed upon interspecies prion transmissions are actually strain barriers. This notion of strain barriers has significant implications: one cannot assume that because one or more strains derived from a given species, such as sheep, do not appear to be pathogenic in another species, such as humans, that this association will extend to all strains.
Properties of BSE, vCJD, and scrapie prions in Tg(BoPrP) mice. The vCJD strain appears unique among human prion strains, since all others tested were not transmissible to Tg(BoPrP) mice (Table 1). These data are consistent with the proposition that prion strains represent different conformers of PrPSc (5, 40, 61). As vCJD appears to be BSE that has passed from cattle to humans (7, 15, 24, 58, 65, 66), we infer that the vCJD prions exist in a PrPSc conformation that is compatible with the sequence of both BoPrP and human (Hu) PrP and that other human prion strains are conformers that are incompatible with the sequence of BoPrP, presumably due to steric hindrances. In contrast to vCJD prions, scrapie prions of Suffolk sheep transmitted to Tg(BoPrP) mice with no evidence of a transmission barrier and consistently produced shorter incubation periods than BSE prions in these mice (Fig. 2D and E). Notably, scrapie prions have also been experimentally transmitted to cattle (16, 50). Together, these data suggest that cattle possess some potential to propagate scrapie prions efficiently, although other factors may prevent pathogenesis by natural modes of transmission.
When the conformational stabilities of BSE and scrapie prions passaged in Tg(BoPrP) mice were compared, BSE prions were much more resistant to GdnHCl denaturation (Fig. 3), even though the original scrapie prions from sheep showed greater relative conformational stability than BSE prions from cattle (Fig. 3). Unfortunately, we were not able to acquire any samples of sheep-passaged BSE prions for comparison, but our studies suggest that measurement of conformational stability may prove useful as a diagnostic procedure in distinguishing BSE prions from scrapie prions in sheep (Fig. 3).
Chimeric PrP transgenes. Our data on the differential susceptibilities of Tg(BoPrP) mice to BSE, scrapie, and various human prion strains led us to consider whether it would be possible to create chimeric mouse-BoPrP transgenes specifically tailored to propagate particular strains. One goal was to create a chimeric transgene that, unlike native BoPrP, is able to confer a high degree of susceptibility to BSE prions while retaining relative resistance to infection with most strains of sheep scrapie. Accordingly, we created the series of chimeric PrPs (Fig. 1) and expressed them in Tg mice. We noted a wide variance in the relative ability of these mice to propagate BSE, vCJD, and scrapie prions (Table 2). On reviewing these results, we were unable to detect any clear relationship between particular segments of PrP and their ability to propagate BSE, vCJD, or scrapie prions. The Bo3M(HVEII) chimera is essentially a perfect replica of BoPrP, with the exception of the extreme C terminus following residue 226 (Fig. 1). Although Tg(Bo3M,HVEII) mice displayed almost identical susceptibility to BSE and vCJD prions compared to Tg(BoPrP) mice (Table 1), they showed a much longer incubation period with scrapie prions (Table 2). The C-terminal region of Bo3M(HVEII) contains a substitution of Lys for Arg at residue 231 and the motif DRG at the extreme C terminus, preceding the GPI cleavage site. It is not known whether one or another of these sequence differences is responsible for the observed difference in susceptibility to scrapie prions.
In Bo3M(HVEIV), a single additional change was made compared to Bo3M(HVEII): a substitution of Val for Ile at residue 226. Unexpectedly, the Tg(Bo3M,HVEIV) mice were completely resistant to BSE, vCJD, and scrapie prions. This is perplexing because this single change was designed to correct a mismatch in Bo3M(HVEII) with the binding motif of protein X, proposed to be required for the propagation of prions in murine cells (28) and Tg mice (29, 42, 62). All other residues in this motif are conserved between BoPrP and MoPrP. Contrary to expectation, all of the chimeric PrPs featuring Val at residue 226 were relatively resistant to all prion inocula, except for the Bo3M(YIQVV) construct (Table 2), which features an intact C-terminal MoPrP subdomain and two unchanged disulfide-linked helices. Tg mice expressing Bo3M(YIQVV) show complete resistance to scrapie prions, moderately short incubation periods with BSE prions (260 days), and short incubation times with vCJD prions (226 days), which is the shortest duration for vCJD prions in any Tg mouse line tested to date. No efficient Tg model for vCJD has yet been developed with human or chimeric human PrP transgenes (14, 29). It will be interesting to test whether a construct analogous to Bo3M(YIQVV) but containing Hu rather than Bo sequences confers enhanced susceptibility to vCJD or other strains of Hu prions.
Distinguishing BSE from scrapie prions in sheep. Three ORFs that we have tested in Tg mice feature Ile at both residues 214 and 226: Bo, Bo3M(HVEII), and Bo3M(YIQII). Mice expressing any one of the three constructs showed short incubation periods (230 days) when inoculated with BSE prions (Table 2). These data seem to indicate that preserving the sequence of helix B and at least part of helix C is desirable for the most efficient transmission of BSE prions. Mice expressing the Bo3M(YIQII) construct showed a substantial difference in susceptibility to BSE and scrapie prions, with incubation periods of 232 and 347 days, respectively, in the Tg(Bo3M,YIQII)23953 line, and 248 and 449 days, respectively, in Tg(Bo3M,YIQII)23939 mice (Table 2). Based on these differences, we selected the Tg(Bo3M,YIQII)23953 line for serial transmission studies and found that the incubation time for Tg(Bo3M,YIQII)-passaged BSE prions shortened from 232 to 170 days, whereas Tg(Bo3M,YIQII)-passaged scrapie prions showed a smaller decrease in the incubation period, from 347 to 313 days (Fig. 4). In light of concerns that BSE prions may have transmitted to sheep, Tg(Bo3M,YIQII) as well as the Tg(Bo3M,YIQVV) mice noted above may be of utility in screening sheep samples for the presence of BSE prions.
PrP amyloid deposition and florid plaques. BSE and vCJD prions caused similar neuropathologic phenotypes in Tg(BoPrP+/+)4092 and Tg(Bo3M,YIQII)23953 mice that were substantially different than those caused by scrapie prions (Fig. 5 and 6). These results agree with those we reported for transmission of BSE, vCJD, and scrapie prions in earlier studies with Tg(BoPrP) mice (58); unlike most established scrapie prion strains (6, 18, 19), BSE and vCJD prions are highly amyloidogenic (58). With respect to amyloid plaque formation, our present understanding is that an amyloidogenic conformation of an infecting PrPSc is imposed on the host's PrPC. Perhaps this amyloidogenic conformation favors natural truncation of PrPSc or presents surfaces that favor polymerization of PrPSc into amyloid filaments. Interestingly, the amyloid plaques formed in Tg(BoPrP+/+)4092 and Tg(Bo3M,YIQII)23953 mice resemble the florid plaques that are pathognomonic for vCJD in humans (66).
Earlier studies indicated that both the prion strain and the host genotype determine whether or not amyloid plaques form (6, 18, 19). Therefore, it is reasonable to hypothesize that the amino acid sequence of Bo3M(YIQII) expressed in Tg(Bo3M,YIQII)23953 mice enhances amyloid plaque formation, thereby causing the massive deposits of amyloid found from BSE and vCJD prions (Fig. 6A, B, E, and F).
Transgenes optimized for propagation of specific prion strains may provide faster and more efficient bioassays with animals, cultured cells, or cell-free systems. Unfortunately, it is not yet possible to predict whether a particular PrP sequence will confer susceptibility to any prion strain originating in a species with a different PrP sequence, although our work suggests that slight variations in or near all three helices of PrP can profoundly affect susceptibility in a strain-dependent manner. Our studies raise concerns that differences in the sequence of PrP may not be relied upon for protection from infection from prions of other species. Instead, susceptibility to prions appears to depend on both the sequence of PrP and the strain of prion, a conclusion that has serious implications for assessing the potential of prions to jump from one species, such as sheep or cattle, to another species, such as humans.
ACKNOWLEDGMENTS
This work was supported by grants from the National Institutes of Health (AG02132, AG10770, and AG021601) as well as by a gift from the G. Harold and Leila Y. Mathers Charitable Foundation.
We thank Pierre Lessard and the staff at the Hunters Point animal facility for support with the transgenic animal experiments, Jiri Safar for helpful discussions, Giuseppe Legname for antibodies, Hang Nguyen for expert editorial assistance, and Steve Feist for information technology support.
M.R.S., D.P., S.J.D., and S.B.P. have financial interest in InPro Biotechnology.
REFERENCES
Anderson, R. M., C. A. Donnelly, N. M. Ferguson, M. E. J. Woolhouse, C. J. Watt, H. J. Udy, S. MaWhinney, S. P. Dunstan, T. R. E. Southwood, J. W. Wilesmith, J. B. M. Ryan, L. J. Hoinville, J. E. Hillerton, A. R. Austin, and G. A. H. Wells. 1996. Transmission dynamics and epidemiology of BSE in British cattle. Nature 382:779-788.
Barlow, R. M., and J. C. Rennie. 1976. The fate of ME7 scrapie infection in rats, guinea-pigs and rabbits. Res. Vet. Sci. 21:110-111.
Barron, R. M., V. Thomson, E. Jamieson, D. W. Melton, J. Ironside, R. Will, and J. C. Manson. 2001. Changing a single amino acid in the N-terminus of murine PrP alters TSE incubation time across three species barriers. EMBO J. 20:5070-5078.
Basler, K., B. Oesch, M. Scott, D. Westaway, M. W?lchli, D. F. Groth, M. P. McKinley, S. B. Prusiner, and C. Weissmann. 1986. Scrapie and cellular PrP isoforms are encoded by the same chromosomal gene. Cell 46:417-428.
Bessen, R. A., and R. F. Marsh. 1994. Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy. J. Virol. 68:7859-7868.
Bruce, M. E., A. G. Dickinson, and H. Fraser. 1976. Cerebral amyloidosis in scrapie in the mouse: effect of agent strain and mouse genotype. Neuropathol. Appl. Neurobiol. 2:471-478.
Bruce, M. E., R. G. Will, J. W. Ironside, I. McConnell, D. Drummond, A. Suttie, L. McCardle, A. Chree, J. Hope, C. Birkett, S. Cousens, H. Fraser, and C. J. Bostock. 1997. Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent. Nature 389:498-501.
Buchanan, C. R., M. A. Preece, and R. D. G. Milner. 1991. Mortality, neoplasia and Creutzfeldt-Jakob disease in patients treated with pituitary growth hormone in the United Kingdom. Br. Med. J. 302:824-828.
Büeler, H., M. Fisher, Y. Lang, H. Bluethmann, H.-P. Lipp, S. J. DeArmond, S. B. Prusiner, M. Aguet, and C. Weissmann. 1992. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356:577-582.
Carlson, G. A., C. Ebeling, S.-L. Yang, G. Telling, M. Torchia, D. Groth, D. Westaway, S. J. DeArmond, and S. B. Prusiner. 1994. Prion isolate specified allotypic interactions between the cellular and scrapie prion proteins in congenic and transgenic mice. Proc. Natl. Acad. Sci. USA 91:5690-5694.
Carlson, G. A., P. A. Goodman, M. Lovett, B. A. Taylor, S. T. Marshall, M. Peterson-Torchia, D. Westaway, and S. B. Prusiner. 1988. Genetics and polymorphism of the mouse prion gene complex: control of scrapie incubation time. Mol. Cell. Biol. 8:5528-5540.
Caughey, B. W., A. Dong, K. S. Bhat, D. Ernst, S. F. Hayes, and W. S. Caughey. 1991. Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy. Biochemistry 30:7672-7680.
Chapman, J., J. Ben-Israel, Y. Goldhammer, and A. D. Korczyn. 1994. The risk of developing Creutzfeldt-Jakob disease in subjects with the PRNP gene codon 200 point mutation. Neurology 44:1683-1686.
Collinge, J., M. S. Palmer, K. C. Sidle, A. F. Hill, I. Gowland, J. Meads, E. Asante, R. Bradley, L. J. Doey, and P. L. Lantos. 1995. Unaltered susceptibility to BSE in transgenic mice expressing human prion protein. Nature 378:779-783.
Collinge, J., K. C. L. Sidle, J. Meads, J. Ironside, and A. F. Hill. 1996. Molecular analysis of prion strain variation and the aetiology of "new variant" CJD. Nature 383:685-690.
Cutlip, R. C., J. M. Miller, and H. D. Lehmkuhl. 1997. Second passage of a U.S. scrapie agent in cattle. J. Comp. Pathol. 117:271-275.
Ferguson, N. M., C. A. Donnelly, M. E. Woolhouse, and R. M. Anderson. 1997. The epidemiology of BSE in cattle herds in Great Britain. II. Model construction and analysis of transmission dynamics. Philos. Trans. R. Soc. Lond. B 352:803-838.
Fraser, H., and M. E. Bruce. 1973. Argyrophilic plaques in mice inoculated with scrapie from particular sources. Lancet i:617.
Fraser, H., and M. E. Bruce. 1983. Experimental control of cerebral amyloid in scrapie in mice, p. 281-290. In P. O. Behan, V. ter Meulen, and F. C. Rose (ed.), Immunology of nervous system infections. Progress in brain research, vol. 59. Elsevier Science Publishers, Amsterdam, The Netherlands.
Gibbs, C. J., Jr., and D. C. Gajdusek. 1973. Experimental subacute spongiform virus encephalopathies in primates and other laboratory animals. Science 182:67-68.
Gibbs, C. J., Jr., D. C. Gajdusek, D. M. Asher, M. P. Alpers, E. Beck, P. M. Daniel, and W. B. Matthews. 1968. Creutzfeldt-Jakob disease (spongiform encephalopathy): transmission to the chimpanzee. Science 161:388-389.
Goldgaber, D., L. G. Goldfarb, P. Brown, D. M. Asher, W. T. Brown, S. Lin, J. W. Teener, S. M. Feinstone, R. Rubenstein, R. J. Kascsak, J. W. Boellaard, and D. C. Gajdusek. 1989. Mutations in familial Creutzfeldt-Jakob disease and Gerstmann-Str?ussler-Scheinker's syndrome. Exp. Neurol. 106:204-206.
Hill, A. F., and J. Collinge. 2003. Subclinical prion infection in humans and animals. Br. Med. Bull. 66:161-170.
Hill, A. F., M. Desbruslais, S. Joiner, K. C. L. Sidle, I. Gowland, J. Collinge, L. J. Doey, and P. Lantos. 1997. The same prion strain causes vCJD and BSE. Nature 389:448-450.
Hill, A. F., S. Joiner, J. Linehan, M. Desbruslais, P. L. Lantos, and J. Collinge. 2000. Species-barrier-independent prion replication in apparently resistant species. Proc. Natl. Acad. Sci. USA 97:10248-10253.
Hope, J., L. Ritchie, C. Farquhar, R. Somerville, and N. Hunter. 1989. Bovine spongiform encephalopathy: a scrapie-like disease of British cattle. Prog. Clin. Biol. Res. 317:659-667.
Hsiao, K., Z. Meiner, E. Kahana, C. Cass, I. Kahana, D. Avrahami, G. Scarlato, O. Abramsky, S. B. Prusiner, and R. Gabizon. 1991. Mutation of the prion protein in Libyan Jews with Creutzfeldt-Jakob disease. N. Engl. J. Med. 324:1091-1097.
Kaneko, K., L. Zulianello, M. Scott, C. M. Cooper, A. C. Wallace, T. L. James, F. E. Cohen, and S. B. Prusiner. 1997. Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc. Natl. Acad. Sci. USA 94:10069-10074.
Korth, C., K. Kaneko, D. Groth, N. Heye, G. Telling, J. Mastrianni, P. Parchi, P. Gambetti, R. Will, J. Ironside, C. Heinrich, P. Tremblay, S. J. DeArmond, and S. B. Prusiner. 2003. Abbreviated incubation times for human prions in mice expressing a chimeric mouse-human prion protein transgene. Proc. Natl. Acad. Sci. USA 100:4784-4789.
Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
Lasmézas, C. I., J.-P. Deslys, R. Demaimay, K. T. Adjou, F. Lamoury, D. Dormont, O. Robain, J. Ironside, and J.-J. Hauw. 1996. BSE transmission to macaques. Nature 381:743-744.
Lasmézas, C. I., J.-P. Deslys, O. Robain, A. Jaegly, V. Beringue, J.-M. Peyrin, J.-G. Fournier, J.-J. Hauw, J. Rossier, and D. Dormont. 1997. Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. Science 275:402-405.
Liu, H., S. Farr-Jones, N. B. Ulyanov, M. Llinas, S. Marqusee, D. Groth, F. E. Cohen, S. B. Prusiner, and T. L. James. 1999. Solution structure of Syrian hamster prion protein rPrP(90-231). Biochemistry 38:5362-5377.
Manson, J. C., E. Jameison, H. Baybutt, N. L. Tuzi, R. Barron, I. McConnell, R. Somerville, J. Ironside, R. Will, M.-S. Sy, D. W. Melton, J. Hope, and C. Bostock. 1999. A single amino acid alteration (101L) introduced into murine PrP dramatically alters incubation time of transmissible spongiform encephalopathy. EMBO J. 18:6855-6864.
Muramoto, T., T. Kitamoto, J. Tateishi, and I. Goto. 1992. The sequential development of abnormal prion protein accumulation in mice with Creutzfeldt-Jakob disease. Am. J. Pathol. 140:1411-1420.
Nishida, N., D. A. Harris, D. Vilette, H. Laude, Y. Frobert, J. Grassi, D. Casanova, O. Milhavet, and S. Lehmann. 2000. Successful transmission of three mouse-adapted scrapie strains to murine neuroblastoma cell lines overexpressing wild-type mouse prion protein. J. Virol. 74:320-325.
Pan, K.-M., M. Baldwin, J. Nguyen, M. Gasset, A. Serban, D. Groth, I. Mehlhorn, Z. Huang, R. J. Fletterick, F. E. Cohen, and S. B. Prusiner. 1993. Conversion of -helices into ?-sheets features in the formation of the scrapie prion proteins. Proc. Natl. Acad. Sci. USA 90:10962-10966.
Pattison, I. H. 1965. Experiments with scrapie with special reference to the nature of the agent and the pathology of the disease, p. 249-257. In D. C. Gajdusek, C. J. Gibbs, Jr., and M. P. Alpers (ed.), Slow, latent and temperate virus infections. NINDB monograph 2. U.S. Government Printing Office, Washington, D.C.
Peretz, D., M. Scott, D. Groth, A. Williamson, D. Burton, F. E. Cohen, and S. B. Prusiner. 2001. Strain-specified relative conformational stability of the scrapie prion protein. Protein Sci. 10:854-863.
Peretz, D., R. A. Williamson, G. Legname, Y. Matsunaga, J. Vergara, D. Burton, S. J. DeArmond, S. B. Prusiner, and M. R. Scott. 2002. A change in the conformation of prions accompanies the emergence of a new prion strain. Neuron 34:921-932.
Peretz, D., R. A. Williamson, Y. Matsunaga, H. Serban, C. Pinilla, R. B. Bastidas, R. Rozenshteyn, T. L. James, R. A. Houghten, F. E. Cohen, S. B. Prusiner, and D. R. Burton. 1997. A conformational transition at the N-terminus of the prion protein features in formation of the scrapie isoform. J. Mol. Biol. 273:614-622.
Perrier, V., K. Kaneko, J. Safar, J. Vergara, P. Tremblay, S. J. DeArmond, F. E. Cohen, S. B. Prusiner, and A. C. Wallace. 2002. Dominant-negative inhibition of prion replication in transgenic mice. Proc. Natl. Acad. Sci. USA 99:13079-13084.
Prusiner, S. B. 1999. Development of the prion concept, p. 67-112. In S. B. Prusiner (ed.), Prion biology and diseases. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
Prusiner, S. B., D. Groth, A. Serban, R. Koehler, D. Foster, M. Torchia, D. Burton, S.-L. Yang, and S. J. DeArmond. 1993. Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc. Natl. Acad. Sci. USA 90:10608-10612.
Prusiner, S. B., D. F. Groth, D. C. Bolton, S. B. Kent, and L. E. Hood. 1984. Purification and structural studies of a major scrapie prion protein. Cell 38:127-134.
Prusiner, S. B., M. P. McKinley, K. A. Bowman, D. C. Bolton, P. E. Bendheim, D. F. Groth, and G. G. Glenner. 1983. Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 35:349-358.
Prusiner, S. B., M. Scott, D. Foster, K.-M. Pan, D. Groth, C. Mirenda, M. Torchia, S.-L. Yang, D. Serban, G. A. Carlson, P. C. Hoppe, D. Westaway, and S. J. DeArmond. 1990. Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication. Cell 63:673-686.
Race, R. E., S. A. Priola, R. A. Bessen, D. Ernst, J. Dockter, G. F. Rall, L. Mucke, B. Chesebro, and M. B. A. Oldstone. 1995. Neuron-specific expression of a hamster prion protein minigene in transgenic mice induces susceptibility to hamster scrapie agent. Neuron 15:1183-1191.
Riek, R., S. Hornemann, G. Wider, M. Billeter, R. Glockshuber, and K. Wüthrich. 1996. NMR structure of the mouse prion protein domain PrP(121-231). Nature 382:180-182.
Robinson, M. M., W. J. Hadlow, D. P. Knowles, T. P. Huff, P. A. Lacy, R. F. Marsh, and J. R. Gorham. 1995. Experimental infection of cattle with the agents of transmissible mink encephalopathy and scrapie. J. Comp. Pathol. 113:241-251.
Safar, J., P. P. Roller, D. C. Gajdusek, and C. J. Gibbs, Jr. 1993. Conformational transitions, dissociation, and unfolding of scrapie amyloid (prion) protein. J. Biol. Chem. 268:20276-20284.
Safar, J., H. Wille, V. Itri, D. Groth, H. Serban, M. Torchia, F. E. Cohen, and S. B. Prusiner. 1998. Eight prion strains have PrPSc molecules with different conformations. Nat. Med. 4:1157-1165.
Safar, J. G., M. Scott, J. Monaghan, C. Deering, S. Didorenko, J. Vergara, H. Ball, G. Legname, E. Leclerc, L. Solforosi, H. Serban, D. Groth, D. R. Burton, S. B. Prusiner, and R. A. Williamson. 2002. Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nat. Biotechnol. 20:1147-1150.
Scott, M., D. Foster, C. Mirenda, D. Serban, F. Coufal, M. W?lchli, M. Torchia, D. Groth, G. Carlson, S. J. DeArmond, D. Westaway, and S. B. Prusiner. 1989. Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques. Cell 59:847-857.
Scott, M., D. Groth, D. Foster, M. Torchia, S.-L. Yang, S. J. DeArmond, and S. B. Prusiner. 1993. Propagation of prions with artificial properties in transgenic mice expressing chimeric PrP genes. Cell 73:979-988.
Scott, M. R., R. K?hler, D. Foster, and S. B. Prusiner. 1992. Chimeric prion protein expression in cultured cells and transgenic mice. Protein Sci. 1:986-997.
Scott, M. R., J. Safar, G. Telling, O. Nguyen, D. Groth, M. Torchia, R. Koehler, P. Tremblay, D. Walther, F. E. Cohen, S. J. DeArmond, and S. B. Prusiner. 1997. Identification of a prion protein epitope modulating transmission of bovine spongiform encephalopathy prions to transgenic mice. Proc. Natl. Acad. Sci. USA 94:14279-14284.
Scott, M. R., R. Will, J. Ironside, H.-O. B. Nguyen, P. Tremblay, S. J. DeArmond, and S. B. Prusiner. 1999. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc. Natl. Acad. Sci. USA 96:15137-15142.
Spudich, S., J. A. Mastrianni, M. Wrensch, R. Gabizon, Z. Meiner, I. Kahana, H. Rosenmann, E. Kahana, and S. B. Prusiner. 1995. Complete penetrance of Creutzfeldt-Jakob disease in Libyan Jews carrying the E200K mutation in the prion protein gene. Mol. Med. 1:607-613.
Supattapone, S., P. Bosque, T. Muramoto, H. Wille, C. Aagaard, D. Peretz, H.-O. B. Nguyen, C. Heinrich, M. Torchia, J. Safar, F. E. Cohen, S. J. DeArmond, S. B. Prusiner, and M. Scott. 1999. Prion protein of 106 residues creates an artificial transmission barrier for prion replication in transgenic mice. Cell 96:869-878.
Telling, G. C., P. Parchi, S. J. DeArmond, P. Cortelli, P. Montagna, R. Gabizon, J. Mastrianni, E. Lugaresi, P. Gambetti, and S. B. Prusiner. 1996. Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science 274:2079-2082.
Telling, G. C., M. Scott, J. Mastrianni, R. Gabizon, M. Torchia, F. E. Cohen, S. J. DeArmond, and S. B. Prusiner. 1995. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell 83:79-90.
Tremblay, P., Z. Meiner, M. Galou, C. Heinrich, C. Petromilli, T. Lisse, J. Cayetano, M. Torchia, W. Mobley, H. Bujard, S. J. DeArmond, and S. B. Prusiner. 1998. Doxycyline control of prion protein transgene expression modulates prion disease in mice. Proc. Natl. Acad. Sci. USA 95:12580-12585.
Westaway, D., V. Zuliani, C. M. Cooper, M. Da Costa, S. Neuman, A. L. Jenny, L. Detwiler, and S. B. Prusiner. 1994. Homozygosity for prion protein alleles encoding glutamine-171 renders sheep susceptible to natural scrapie. Genes Dev. 8:959-969.
Will, R. G., S. N. Cousens, C. P. Farrington, P. G. Smith, R. S. G. Knight, and J. W. Ironside. 1999. Deaths from variant Creutzfeldt-Jakob disease. Lancet 353:979.
Will, R. G., J. W. Ironside, M. Zeidler, S. N. Cousens, K. Estibeiro, A. Alperovitch, S. Poser, M. Pocchiari, A. Hofman, and P. G. Smith. 1996. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347:921-925.
Wille, H., M. D. Michelitsch, V. Guénebaut, S. Supattapone, A. Serban, F. E. Cohen, D. A. Agard, and S. B. Prusiner. 2002. Structural studies of the scrapie prion protein by electron crystallography. Proc. Natl. Acad. Sci. USA 99:3563-3568.
Williams, E. S., and S. Young. 1982. Spongiform encephalopathy of Rocky Mountain Elk. J. Wildl. Dis. 18:465-471.(Michael R. Scott, David P)
Biochemistry and Biophysics, University of California, San Francisco, California
ABSTRACT
Transgenic (Tg) mice expressing full-length bovine prion protein (BoPrP) serially propagate bovine spongiform encephalopathy (BSE) prions without posing a transmission barrier. These mice also posed no transmission barrier for Suffolk sheep scrapie prions, suggesting that cattle may be highly susceptible to some sheep scrapie strains. Tg(BoPrP) mice were also found to be susceptible to prions from humans with variant Creutzfeldt-Jakob disease (CJD); on second passage in Tg(BoPrP) mice, the incubation times shortened by 30 to 40 days. In contrast, Tg(BoPrP) mice were not susceptible to sporadic, familial, or iatrogenic CJD prions. While the conformational stabilities of bovine-derived and Tg(BoPrP)-passaged BSE prions were similar, the stability of sheep scrapie prions was higher than that found for the BSE prions but lower if the scrapie prions were passaged in Tg(BoPrP) mice. Our findings suggest that BSE prions did not arise from a sheep scrapie strain like the one described here; rather, BSE prions may have arisen spontaneously in a cow or by passage of a scrapie strain that maintains its stability upon passage in cattle. It may be possible to distinguish BSE prions from scrapie strains in sheep by combining conformational stability studies with studies using novel Tg mice expressing a chimeric mouse-BoPrP gene. Single-amino-acid substitutions in chimeric PrP transgenes produced profound changes in incubation times that allowed us to distinguish prions causing BSE from those causing scrapie.
INTRODUCTION
Prion diseases are fatal degenerative disorders of the central nervous system (CNS). The pathogenesis of prion diseases involves conversion of the host-encoded prion protein (PrP), denoted PrPC, into an insoluble isoform (PrPSc) that accumulates in the CNS. PrPSc is the only known component of the infectious pathogen (43). PrPC undergoes a profound conformational change as PrPSc is formed; this structural transition is characterized by an increase in ?-sheet content and the disappearance of several surface epitopes (12, 33, 37, 41, 46, 49, 51, 67). Moreover, this conformational change is the fundamental event in prion replication.
To distinguish PrPSc from PrPC, limited digestion with proteases is commonly employed, during which PrPC is readily digested and PrPSc is N-terminally truncated to form PrP 27-30 (4, 45, 46). Concerned that proteolytic digestion was destroying a significant portion of PrPSc, one of us (S.B.P.) developed the conformation-dependent immunoassay (CDI) for measuring PrPSc. The CDI uses antibodies directed to epitopes that are exposed in PrPC but buried in native PrPSc (52). The buried epitope in PrPSc becomes exposed upon denaturation, and the difference in immunoreactivities between the denatured sample and the native sample is equal to PrPSc. From studies with the CDI, we learned that a minority of PrPSc molecules are protease resistant and that we had underestimated the level of PrPSc b yas much as 90% in some instances. These results indicated that PrPSc adopts both protease-resistant (r) and -sensitive (s) conformations.
Bovine spongiform encephalopathy (BSE) (26) of cattle and chronic wasting disease of deer and elk (68) were recognized as new prion diseases in the 1980s. It has been estimated that 750,000 cattle infected with BSE prions were slaughtered for human consumption in Great Britain during a period spanning from 1980 to 1996 (1, 17). It now seems clear that during this period, the disease passed to humans through the consumption of contaminated beef products, leading to the emergence of a new, variant form of Creutzfeldt-Jakob disease (vCJD). While epidemiological studies (65, 66) and prion strain typing experiments (7, 15, 24) suggested that vCJD is caused by the transmission of BSE prions to humans, compelling evidence arguing for an etiologic link between BSE and vCJD came from the demonstration that human vCJD prions precisely recapitulate the properties of bovine BSE prions following transmission to transgenic (Tg) mice expressing bovine prion protein (BoPrP) (58).
Although it is clear that vCJD in humans is caused by BSE prions, it is unknown what proportion of those exposed to BSE prions will eventually develop vCJD. Moreover, it is not known whether consumption of chronic wasting disease-tainted venison poses a risk to humans. Although prion diseases are not generally communicable, experimental transmission of prion diseases between hosts of the same mammalian species is typically highly efficient, with a uniform and consistent incubation period. In contrast, prion transmission between animals of different species often fails to cause disease even after prolonged incubation periods. This comparative resistance to infection, as seen in the first passage to a new species, has been termed the species barrier (38).
Studies with Tg mice (47, 48, 54, 55, 57, 62), mice with deficient endogenous PrP gene (Prnp0/0) expression (9, 44), and homologous recombinants (3, 34) established the role of the PrP sequence in modulating susceptibility to foreign prions. However, the work presented here and elsewhere (29) demonstrate that the strain of prion may eliminate the transmission barrier imposed by sequence differences and vice versa. In some cases, a chimeric or mutated gene may be able to confer greater susceptibility to prions, provided that the new PrP sequence is compatible with the prion strain in the inoculum.
Tg(BoPrP) mice are highly susceptible to BSE prions, and the infected animals faithfully recapitulate many of the features of BSE in cattle (57). These same mice are also highly susceptible to both vCJD and natural sheep scrapie prions (58). We developed a new line of Tg mice homozygous for the BoPrP transgene, and this facilitated the breeding of large numbers of animals required for an endpoint titration study (53). The titers obtained, which were equal to or greater than 107 infectious units per gram of tissue, indicated that these Tg mice are 10-fold more susceptible than cattle and 104-fold more sensitive than wild-type mice to BSE prions (53). We presume that the heightened sensitivity of these Tg mice to BSE prions compared to cattle is a consequence of the overexpression of BoPrP (11, 47, 63). Overexpression of PrP in mouse neuroblastoma cells also appears to increase the susceptibility of these cells to infection with mouse prion strains (36).
In the study reported here, we demonstrate that some isolates of sheep scrapie prions transmit very efficiently to Tg(BoPrP) mice, with no evidence of a prion transmission barrier. In contrast, vCJD prions transmit less efficiently, with an 30-day change in incubation period from first to second passage. Tg(BoPrP) mice were resistant to all other human prions tested. We next created a series of chimeric mouse-BoPrP transgenes and showed that they confer various degrees of susceptibility to BSE, vCJD, and scrapie prions. One line of Tg mice appear highly susceptible to BSE prions but not to scrapie prions and may be suitable for selectively identifying BSE strains in sheep.
MATERIALS AND METHODS
Chimeric transgenes and production of transgenic mice. Tg(BoPrP)4125 and Tg(BoPrP+/+)4092 mice have been described previously (53, 57, 58). The Bo3M open reading frame (ORF) was created by replacing the N-terminal coding sequence of the MBo2M chimera (58) with the corresponding sequence from the native BoPrP ORF cassette (58). This exchange of sequences exploited the presence of a single PstI restriction enzyme cleavage site that cleaves within the homologous BoPrP-derived sequences. Additional chimeric PrP transgenes were created by replacing regions of the Bo3MPrP ORF with synthetic double-stranded DNA oligonucleotides to create a series of chimeras (Fig. 1). Complete sequences of the chimeric ORF constructs in GenBank-compatible format were determined (data not shown). Plasmid manipulations were prototyped, and sequences were archived by using Vector NTI software (Informax, Inc., Frederick, Md.).
Prion isolates and transmission studies. BSE isolates from samples GJ248/85, SE1809/11, 97/1612, 97/1997, and PG31/90 were obtained from John Wilesmith at the Central Veterinary Laboratory, Weybridge, United Kingdom. Brain samples from vCJD cases RU96/02, RU96/07, RU96/70, RU96/80, and RU96/110 were obtained from Robert Will and James Ironside at the United Kingdom National CJD Surveillance Unit. Sheep scrapie isolates Oreo, T97-1104, no. 15, no. 139, and no. 340 have been described elsewhere (58, 64), and all are derived from Suffolk sheep with the ARQ genotype. Tg(BoPrP)-passaged BSE, vCJD, and scrapie isolates were produced in this laboratory and have been described in previous publications (53, 57, 58). Transmissions of the BSE, vCJD, and scrapie isolates to Tg mice were performed as previously described (57). Brain samples used for transmission studies are listed in the figure legends. Brain homogenates were prepared by repeated extrusion through syringe needles of successively smaller sizes, from 22 to 18 gauge. Mice were inoculated with 30 μl of a 1% homogenate (wt/vol) in sterile phosphate-buffered saline without Ca2+ or Mg2+ by using a 27-gauge, disposable hypodermic needle inserted into the right parietal lobe. Following inoculation, the status of the mice was monitored daily while the neurologic status was assessed three times per week. Clinical diagnosis was performed as previously described (11, 55).
Neuropathology. Brains were removed rapidly from animals and either perfusion fixed in 10% buffered formalin or snap-frozen. The brains were embedded in paraffin, and histological sections were stained with hematoxylin and eosin for evaluation of vacuolar (spongiform) degeneration. Vacuolation scores, which are semiquantitative estimates of a brain region occupied by vacuoles (10), were determined by a single rater (S.J.D.). Immunohistochemical localization of PrPSc on formalin-fixed, paraffin-embedded tissue sections was determined by the formic acid-hydrated autoclaving method (35). Sections of formalin-fixed, paraffin-embedded tissue on glass slides were immersed in undiluted formic acid for 2 min followed by autoclaving in 1.3 mM HCl in distilled H2O for 10 min at 121°C. Sections were then incubated overnight at 4°C with the rabbit BoPrP-specific 9095 antiserum (57). After rinsing, the sections were incubated for 30 min at room temperature with biotinylated anti-rabbit antiserum (Vector Laboratories, Burlingame, Calif.) diluted 1:100 in 5% nonfat milk. Following rinses, color was developed with diaminobenzidine.
Preparation of brain homogenates and conformational stability assays. Aliquots of 1% (wt/vol) brain homogenates were added to an equal volume of stock solutions containing increasing concentrations of GdnHCl, chosen to produce the range of final concentrations of GdnHCl indicated in the figure legends. GdnHCl stock solutions were prepared from an 8 M solution (Pierce, Rockford, Ill.) diluted in water. Following 1 h of incubation at room temperature, all samples were diluted with Tris-buffered saline containing 2% Sarkosyl to a final concentration of 0.4 M GdnHCl. Proteinase K was added in a ratio of 1:500, proteinase K-protein (wt/wt), and digested for 1 h at 37°C. The reaction was stopped with 2 mM phenylmethylsulfonyl fluoride. Protease-resistant, insoluble proteins were collected by centrifugation at 50,000 x g for 1 h at 4°C. Pellets were resuspended in lysis buffer (10 mM Tris-Cl [pH 8.0], 0.15 M NaCl, 0.5% NP-40 [wt/vol], 0.5% sodium deoxycholate [wt/vol]), then an equal volume of 2x sodium dodecyl sulfate sample buffer (30) was added, and the mixture was boiled for 3 min prior to electrophoresis. Sodium dodecyl sulfate gel electrophoresis and Western blotting were performed as previously described (57, 58). PrP was detected by using the humanized clone P recombinant antibody (53) and developed by using the enhanced chemiluminescence detection system (Amersham Biosciences, Piscataway, N.J.) as previously described (58).
RESULTS
Susceptibility of Tg(BoPrP) mice to BSE prions. In earlier studies, we presented evidence that transgene-directed expression of BoPrP in Prnp0/0 mice conferred susceptibility to BSE prions (57, 58). Originally, we reported the development of two Tg lines, Tg(BoPrP)4125 and Tg(BoPrP)4092 (57, 58). Of the two, the Tg(BoPrP)4125 line, consistently yielded shorter incubation periods with BSE inocula, a result we attribute to the 2-fold higher level of BoPrP expression, as expected from previous studies on the relationship between the level of PrP expression and the length of the incubation period (10, 47).
Tg(BoPrP)4125 mice were inoculated with multiple isolates containing BSE prions, derived from both infected cattle and Tg(BoPrP) mice (Fig. 2). In these mice, the average incubation period of BSE prions derived from infected cows (240 days) is not significantly different from that obtained with prions derived from BSE-infected Tg(BoPrP) mouse brain (Fig. 2A). Furthermore, when the number of surviving animals was plotted against the incubation period, the curves obtained were superimposable (Fig. 2A). The neuropathologic changes caused by bovine-derived and Tg(BoPrP) mouse-passaged BSE inocula were also indistinguishable (58). By all available criteria, BSE prions were unchanged by serial passage in Tg(BoPrP) mice. This result contrasts with corresponding studies with non-Tg mice (7, 31, 32), in which a change in incubation period from >300 to 150 days was typically observed from the first to second passage. Recent evidence suggests that both the physical properties and pathogenicity of a prion strain may change dramatically when a change in incubation period is observed from first to second passage (40).
Breeding large numbers of Tg(BoPrP+/0)4125 and Tg(BoPrP+/0)4092 mice is hampered by the need to screen all progeny for the presence of the transgene because the mice are hemizygous for the BoPrP transgene. In an effort to establish a mouse model better suited for large-scale bioassays of BSE prions, we attempted to breed both of these lines to homozygosity for the BoPrP transgene array. We were not successful with the Tg(BoPrP+/0)4125 line, presumably because of a deleterious insertion site, but were able to establish a line from Tg(BoPrP+/0)4092 that is homozygous for the transgene (53). We have already reported that these new Tg(BoPrP+/+)4092 mice are up to 10x more sensitive to BSE prions than cattle when used for endpoint titration (53). When Tg(BoPrP+/+)4092 mice were challenged with BSE prions from infected cow brain and from infected Tg(BoPrP) mouse brain, we observed incubation periods of 244 and 247 days, respectively (Fig. 2B), similar to incubation periods for Tg(BoPrP+/0)4125 mice (Fig. 2A).
Susceptibility of Tg(BoPrP) mice to human CJD prions. Expression of the BoPrP transgene conferred susceptibility to vCJD prions (58): incubation periods and characteristic neuropathologic features of Tg(BoPrP) mice infected with vCJD prions closely resembled those found in Tg(BoPrP) mice inoculated with BSE prions. Having performed additional studies resulting in a much larger sample size, it is now evident that the average incubation period (270 days) of Tg(BoPrP)4125 mice infected with vCJD prions (Fig. 2C) is 30 days longer than the 240-day average obtained with the same mice infected with BSE prions from cow brain (Fig. 2A). Although the incubation period for BSE prions did not change upon serial transmission (Fig. 2A), a shortening of incubation period was observed when brains taken from vCJD-infected Tg(BoPrP) mice were retransmitted to Tg(BoPrP+/0)4125 mice (Fig. 2C). In Tg(BoPrP+/0)4125 mice, we found that the incubation period of Tg(BoPrP)-passaged vCJD prions (224 days) was slightly shorter than that obtained with either prions from a BSE-infected cow (240 days) or from BSE-infected Tg(BoPrP) mice (236 days). However, this shortening is probably not significant and may be a reflection of a much smaller sample size in this data set (Fig. 2A and C). When Tg(BoPrP+/+)4092 mice were challenged with prions from vCJD-infected human brain and vCJD-infected Tg(BoPrP) mouse brain, we observed incubation periods of 274 and 240 days, respectively (Fig. 2D), consistent with the results obtained with Tg(BoPrP+/0)4125 mice (Fig. 2C). Whether these changes result from a transmission barrier or a difference in the relative titer of prions in the inoculum is currently unknown.
The finding that Tg(BoPrP) mice appear relatively susceptible to human vCJD prions prompted us to test whether they were equally susceptible to other known human prion isolates. Neither Tg(BoPrP+/0)4125 nor Tg(BoPrP+/+)4092 mice displayed any significant sensitivity to multiple isolates of sporadic CJD (21, 62), familial CJD bearing the E200K mutation (13, 22, 27, 59), or iatrogenic CJD (8) (Table 1). These data clearly demonstrate that susceptibility of Tg(BoPrP) mice to human prions is highly strain dependent. A slight difference in incubation periods was observed when Tg(BoPrP)4125 mice were inoculated with vCJD prions (Tables 1 and 2). The difference was slightly greater than expected from the standard errors, but we do not know the cause for this observation. Whether the inocula differ slightly in titer because different portions of the same brain were used to prepare homogenates for inoculation, and this is reflected in different incubation times, remains to be established.
Sensitivity of Tg(BoPrP) mice to challenge with sheep scrapie prions. In an earlier report, we found that the BoPrP transgene conferred susceptibility to 5 sheep scrapie isolates tested, which were all of the ARQ genotype (58). Compiling all of the available data for transmission of sheep scrapie prions in Tg(BoPrP+/0)4125 mice (Fig. 2E), we found that the average incubation period was 225 days, shorter than the duration for BSE prions (Fig. 2A and C), and 100% of inoculated animals developed disease. Although 80% of the infectedTg(BoPrP+/0)4125 mice exhibited symptoms of disease at 200 days, a plot of the data displayed a notable shoulder at 250 to 300 days. Because most of the animals within this group were originally challenged with a single scrapie sample (data not shown), it is possible that these longer incubation periods are indicative of a different scrapie strain. We do not have serial passage data available for the Tg(BoPrP+/0)4125 line.
We challenged Tg(BoPrP+/+)4092 mice with multiple inocula, including both sheep scrapie prions and Tg(BoPrP) mouse-passaged scrapie prions (Fig. 2F). Tg(BoPrP+/+)4092 mice exhibited an abbreviated incubation time (212 days) following inoculation with scrapie prions isolated from Suffolk sheep (Fig. 2F). It is notable that the incubation period of sheep scrapie is 20 to 30 days shorter than is routinely observed with BSE inocula in both Tg(BoPrP) lines (Fig. 2A, B, D, and E). Significantly, the incubation periods obtained withTg(BoPrP+/+)4092 mice inoculated with Tg(BoPrP)-passaged scrapie prions were essentially identical (216 days) to those observed after inoculation with native scrapie prions (Fig. 2F). We conclude that Tg(BoPrP) mice present no detectable transmission barrier to at least some strains of sheep scrapie prions; moreover, Tg(BoPrP) mice are slightly more susceptible to scrapie prions than to BSE prions.
Molecular properties of Tg(BoPrP)-passaged scrapie prions and BSE prions. To distinguish among different prion strains, we developed a method to characterize prion strains biochemically by assessing the relative conformational stability of PrPSc (39, 40). To compare the relative conformational stabilities of Tg(BoPrP)-passaged BSE and scrapie prions, we employed a variation of this technique. Samples of brain homogenates obtained from BSE- or scrapie-infected Tg(BoPrP) mice were exposed to increasing concentrations of GdnHCl, digested with protease to hydrolyze denatured PrP, and subjected to electrophoresis and Western blotting to detect protease-resistant fragments (Fig. 3A). When PrP band intensities were assessed by densitometric analysis, we were able to determine an approximate [GdnHCl]1/2 value, the concentration at which half of PrPSc in the sample is denatured (39, 40) for each of the Tg (BoPrP) mouse-passaged isolates (Fig. 3B). Tg(BoPrP) mouse-passaged BSE prions displayed a higher relative conformational stability (mean [GdnHCl]1/2 value of 2.8 M) than Tg(BoPrP) mouse-passaged scrapie prions ([GdnHCl]1/2 value of 2.3 M) (Fig. 3A and B).
These initial data allowed us to develop a simple procedure for biochemical strain typing based on the resistance of PrPSc to denaturation after exposure to specific concentrations of GdnHCl. For discriminating BSE and scrapie prions, we opted to compare the relative resistance to denaturation with 0, 2.8, and 3.0 M GdnHCl (Fig. 3C to F). As expected from our transmission studies, the relative susceptibilities of BSE prions derived from bovine brain (Fig. 3C) and Tg(BoPrP) mouse brain (Fig. 3E) appeared similar, with a nearly identical proportion of PrPSc surviving denaturation with 3.0 M GdnHCl. With 2.8 M GdnHCl, PrPSc derived from bovine brain appeared to be slightly more resistant to denaturation than PrPSc derived from mouse brain (Fig. 3C and E). Consistent with the data shown in Fig. 3A, we found that scrapie prions passaged in Tg(BoPrP) mice were much more susceptible to GdnHCl denaturation than BSE prions from either cattle or infected Tg(BoPrP) mice. Only a small PrPSc fraction survived exposure to 2.8 M GdnHCl, and almost all PrPSc was denatured after treatment with 3.0 M GdnHCl. However, we were very surprised to find that scrapie prions from ovine brain appeared highly resistant to denaturation with 3.0 M GdnHCl (Fig. 3D). Although the sheep scrapie samples used for conformational stability studies and the inocula for Tg(BoPrP) mice were all from U.S. Suffolk sheep, insufficient amounts of sheep brain prevented us from performing conformational stability studies on matched pairs. Thus, this condition must temper our conclusions.
Chimeric PrP transgenes. We were surprised to find that Tg(BoPrP) mice are highly susceptible to sheep scrapie prions in the brains of asymptomatic U.S. Suffolk sheep and that these mice posed no transmission barrier to sheep prions. Because of heightened concerns that BSE prions may have been passed to the sheep population via contaminated feed, we sought to devise a transgenic mouse that could be used to discriminate BSE prions in sheep from scrapie prions in sheep, even if the BSE strain was present in a mixture of one or more scrapie prion strains. A chimeric PrP transgene, termed MH2M, comprised of sequences derived from Syrian hamster PrP (SHaPrP) fused to N- and C-terminal sequences from mouse (Mo) PrP (56), was shown to exhibit a transmission barrier when challenged with two different SHa prion strains (40). Tg(MH2M) mice showed no transmission barrier when challenged with the SHa drowsy strain, but transmission of the SHa Sc237 strain was prolonged on the first passage compared to subsequent transmission (40). These results suggested that it may be possible to construct an analogous chimeric mouse-BoPrP transgene with the ability to confer a high degree of susceptibility to BSE prions while retaining relative resistance to infection with most strains of sheep scrapie. However, we had previously created Tg mice expressing a chimeric construct analogous to MH2M, designated MBo2M and differing only in that it contained BoPrP instead of SHaPrP sequences (57). Tg(MBo2M) mice were resistant to infection with BSE prions, leading us to conclude that a C-terminal epitope controls susceptibility to BSE (57). We therefore elected to create a series of new mouse-BoPrP chimeric transgenes, with the goal of furthering our understanding of the relationship between PrP sequence and susceptibility.
In creating a series of transgenes, we used variations of the Bo3M construct (Fig. 1), which is comprised of the N-terminal region of BoPrP fused to the C terminus of MoPrP. The C-terminal MoPrP subregion is identical to that in MBo2M. We next identified five residues in Bo3M PrP that lie within the three-helical C-terminal folded domain of PrPC and that differ between BoPrP and MoPrP (Fig. 1). The residues are at positions 166, 195, 197, 214, and 226 and correspond to residues 154, 183, 185, 202, and 214, respectively, in MoPrP. We then substituted each of these residues in Bo3M with its corresponding residue in either BoPrP or MoPrP and named the resulting transgenes by the amino acid residues present at these five locations (Fig. 1). Tg mouse lines expressing each of the chimeric PrPs were established in a Prnp0/0 background, expanded, and then inoculated with BSE, scrapie, or vCJD prions (Table 2). Wherever possible, we selected lines that showed similar levels of expression of chimeric PrPC. When tested with BoPrP-specific antisera, most were found to express 8 to 16 times the amount of BoPrPC found in brains of control cattle. Whereas most lines fell into this category, the Tg(Bo3M,HVEII)7177 line had a higher level of expression (16 to 32 times).
We were surprised to find that relatively small changes in the sequence could cause dramatic differences in relative susceptibility to the three different inocula used. The Bo3M(HVEII) chimera represents BoPrP up to and including residue 226 fused to the C terminus of MoPrP. It therefore comprises the N terminus, helices A and B from BoPrP, and a hybrid helix C comprising BoPrP sequence but with Arg substituted for Lys at residue 231, as found in MoPrP. All remaining C-terminal sequences including the GPI anchor signal sequence are derived from MoPrP. The Tg(Bo3M,HVEII)7187 line showed incubation periods similar to those of Tg(BoPrP)4125 mice when inoculated with BSE prions (235 days) and vCJD prions (273 days), reproducing the characteristic 35- to 40-day difference in incubation period between these two inocula observed in Tg(BoPrP) mice (Table 2). However, we found that Tg(Bo3M,HVEII) mice exhibited a longer incubation period (317 days) than Tg(BoPrP)4125 mice (225 days) after inoculation with sheep scrapie prions (Table 2). Another line, Tg(Bo3M,HVEII)7177, harboring this construct but with a slightly higher level of chimeric PrP expression, gave similar results but showed longer incubation periods with BSE and vCJD prions and a slightly shorter incubation period with scrapie prions (Table 2). It is interesting that despite the high level of expression, this line showed slightly longer incubation periods for 2 of the 3 inocula than the Bo3M(HVEII)7187 line, which had the same transgene but expressed approximately half the amount of PrPC (Table 2). These data show that transmissions between hosts encoding PrPC of different sequences do not necessarily exhibit an inverse relationship between PrPC expression and incubation period with all inocula.
We obtained dramatically different results with the Bo3M(HVEIV) chimera, a construct that is identical to Bo3M(HVEII), except Ile was changed to Val at residue 226, as found in MoPrP. Of the three residues within helix C of Bo3M(HVEII) that differ between BoPrP and MoPrP, two are identical to MoPrP. The third residue, position 214 at the beginning of helix C, is Ile, as found in BoPrP; the corresponding residue in MoPrP is Val at position 202. Tg(Bo3M,HVEIV)14926 mice were resistant to all three inocula, with no animals showing clinical signs at >550 days postinfection. Susceptibility to prion infection was partially restored by replacing an internal region of BoPrP corresponding to the region between helices A and B with corresponding sequences from MoPrP, resulting in the Bo3M(YIQIV) construct. The Tg(Bo3M,YIQIV)10677 line was susceptible to all three inocula but exhibited prolonged incubation periods (Table 2). An additional substitution of Val for Ile at residue 214 (in helix C) produced the Bo3M(YIQVV) chimera (Fig. 1), which harbors the N terminus of BoPrP, including helix A, fused to the two C-terminal helices of MoPrP. The Tg(Bo3M,YIQVV)12138 line produced yet another susceptibility profile, showing shorter incubation periods with vCJD prions than BSE prions but displaying complete resistance to scrapie prions.
Bo3M(YIQII) chimeric transgenes. The foregoing results demonstrate how minute differences in the sequence of PrP can dramatically alter susceptibility to foreign prions. We became particularly interested in results we obtained with the Bo3M(YIQII) chimera (Table 2). The Tg(Bo3M,YIQII)23953 line exhibited a short (232 days) incubation period after inoculation with BSE prions comparable to our Tg(BoPrP) and Tg(Bo3M,HVEII) mice (Table 2). The Tg(Bo3M,YIQII)23953 line also gave a slightly shorter incubation period (255 days) after inoculation with vCJD prions. However, it appeared relatively resistant to scrapie prions, with an incubation period of 350 days. Such a susceptibility profile may be useful in distinguishing scrapie prions from BSE prions in affected sheep.
To characterize these Tg mice further, we performed a serial transmission study (Fig. 4). We found that BSE prions from infected Tg(Bo3M,YIQII) mice gave even shorter incubation periods (170 days) than BSE prions derived from cattle (232 days), whereas only a slight shift in incubation period (from 347 to 313 days) was observed between scrapie prions from sheep and from Tg(Bo3M,YIQII) mice, respectively. We interpret this to mean that there is a smaller strain barrier for transmission of scrapie prions to these mice compared to BSE prions.
Neuropathology in Tg(BoPrP) and Tg(Bo3M,YIQII) mice. Based on the foregoing data, we performed a detailed comparison of the neurohistopathologic changes caused by BSE, vCJD, and scrapie prions during serial passaging in Tg(BoPrP+/+)4092 (Fig. 5) and Tg(Bo3M,YIQII)23953 mice (Fig. 6). Four relevant findings were made: (i) the neuropathologic changes caused by bovine-derived BSE and human-derived vCJD prions were similar in both Tg mouse lines and were significantly different than those caused by sheep-derived scrapie prions; (ii) these similarities and differences were maintained during the second passage; (iii) large aggregates of PrP amyloid plaques were induced by BSE and vCJD prions but not by scrapie prions; (iv) PrP amyloid plaques were exceptionally large in Tg(Bo3M,YIQII)23953 mice infected with BSE and vCJD prions.
Scrapie, BSE, and vCJD prions could be distinguished by the distribution of vacuolation in the gray matter neuropil. Scrapie was characterized by mild to moderate degrees of vacuolation in multiple cerebral hemisphere and brainstem regions, whereas vacuolation in BSE and vCJD prions was confined largely to the raphe nuclei of the brainstem and to the habenula (Fig. 5 M to R and 6B). In Tg(BoPrP+/+)4092 mice, vacuolation of the brainstem caused by BSE and vCJD prions was largely confined to the raphe nuclei in the midline of the tegmentum (Fig. 5C and D). In contrast, scrapie-associated vacuolation was found throughout the brainstem tegmentum. In Tg(Bo3M,YIQII)23953 mice, BSE prions caused vacuolation throughout the brainstem tegmentum, similar to scrapie prions. Because we have reviewed only one vCJD primary transmission (Fig. 6E and F), we remain tentative about the pattern of vacuolation in Tg(Bo3M,YIQII)23953 mice.
Cattle-derived BSE and human-derived vCJD prions induced deposition of large amounts of PrP amyloid beneath the corpus callosum and ependyma of the rostral half of the cerebral hemispheres in both Tg(BoPrP+/+)4092 and Tg(Bo3M,YIQII)23953 mice (Fig. 5A and E; Fig. 6A and E). Mature amyloid was not found in other brain regions. Upon second passage, similar-sized aggregates of PrP amyloid developed in the same rostral cerebral hemisphere locations (Fig. 5B and F; Fig. 6B). The individual plaques forming these aggregates bound Congo red dye, which showed green-gold birefringence in polarized light, verifying that they are amyloid (data not shown). The plaques varied in size from 10 to 100 μm in diameter (Fig. 6F). The amyloid aggregates were associated with vacuoles and therefore resemble the florid plaques that are characteristic of vCJD in humans (66) (Fig. 6F). The subcallosal amyloid aggregates in Tg(BoPrP+/+)4092 and Tg(Bo3M,YIQII)23953 mice differed in size. Aggregates were relatively small in the former group, whereas they were massive in the latter group, in which they extended continuously as much as 2 mm in a single coronal section. In contrast to BSE and vCJD prions, no amyloid plaques were formed by scrapie prions upon the first or second passage (Fig. 5I and J).
In addition to mature amyloid plaques, primitive plaque-like deposits of PrPSc arranged singly or in aggregates were also formed by BSE and vCJD prions in both the primary and secondary passages in both Tg mouse lines (Fig. 5C, D, G, and H). These deposits were associated with vacuoles in the gray matter neuropil. In contrast, scrapie prions were associated with small, punctate deposits of PrPSc in association with neuropil vacuolation (Fig. 5K and L).
DISCUSSION
Studies of prion transmission barriers are important in elucidating the fundamental mechanisms of prion replication and critical with respect to the safety of the human food supply. In extreme cases, the host may be incapable of supporting propagation of prions from another species; rabbits appear to be resistant to all prion inocula derived from other species (2, 20) and may present such a bona fide species barrier. More typically, however, a relative difference in susceptibility is manifest by a shortening of the incubation period observed when the first passage is compared to the second and subsequent passages. In recent years, several groups (23, 25, 60) have recognized the need to adopt the more generic term transmission barrier to refer to this difference in susceptibility as defined by a difference in incubation period following transmission to a different species or strain of transgenic animal.
As we have shown, in some cases, a transmission barrier may be evident with certain strains but not others, so we introduce the term strain transmission barrier, or simply strain barrier, to denote this. We propose that the majority of the so-called species barriers observed upon interspecies prion transmissions are actually strain barriers. This notion of strain barriers has significant implications: one cannot assume that because one or more strains derived from a given species, such as sheep, do not appear to be pathogenic in another species, such as humans, that this association will extend to all strains.
Properties of BSE, vCJD, and scrapie prions in Tg(BoPrP) mice. The vCJD strain appears unique among human prion strains, since all others tested were not transmissible to Tg(BoPrP) mice (Table 1). These data are consistent with the proposition that prion strains represent different conformers of PrPSc (5, 40, 61). As vCJD appears to be BSE that has passed from cattle to humans (7, 15, 24, 58, 65, 66), we infer that the vCJD prions exist in a PrPSc conformation that is compatible with the sequence of both BoPrP and human (Hu) PrP and that other human prion strains are conformers that are incompatible with the sequence of BoPrP, presumably due to steric hindrances. In contrast to vCJD prions, scrapie prions of Suffolk sheep transmitted to Tg(BoPrP) mice with no evidence of a transmission barrier and consistently produced shorter incubation periods than BSE prions in these mice (Fig. 2D and E). Notably, scrapie prions have also been experimentally transmitted to cattle (16, 50). Together, these data suggest that cattle possess some potential to propagate scrapie prions efficiently, although other factors may prevent pathogenesis by natural modes of transmission.
When the conformational stabilities of BSE and scrapie prions passaged in Tg(BoPrP) mice were compared, BSE prions were much more resistant to GdnHCl denaturation (Fig. 3), even though the original scrapie prions from sheep showed greater relative conformational stability than BSE prions from cattle (Fig. 3). Unfortunately, we were not able to acquire any samples of sheep-passaged BSE prions for comparison, but our studies suggest that measurement of conformational stability may prove useful as a diagnostic procedure in distinguishing BSE prions from scrapie prions in sheep (Fig. 3).
Chimeric PrP transgenes. Our data on the differential susceptibilities of Tg(BoPrP) mice to BSE, scrapie, and various human prion strains led us to consider whether it would be possible to create chimeric mouse-BoPrP transgenes specifically tailored to propagate particular strains. One goal was to create a chimeric transgene that, unlike native BoPrP, is able to confer a high degree of susceptibility to BSE prions while retaining relative resistance to infection with most strains of sheep scrapie. Accordingly, we created the series of chimeric PrPs (Fig. 1) and expressed them in Tg mice. We noted a wide variance in the relative ability of these mice to propagate BSE, vCJD, and scrapie prions (Table 2). On reviewing these results, we were unable to detect any clear relationship between particular segments of PrP and their ability to propagate BSE, vCJD, or scrapie prions. The Bo3M(HVEII) chimera is essentially a perfect replica of BoPrP, with the exception of the extreme C terminus following residue 226 (Fig. 1). Although Tg(Bo3M,HVEII) mice displayed almost identical susceptibility to BSE and vCJD prions compared to Tg(BoPrP) mice (Table 1), they showed a much longer incubation period with scrapie prions (Table 2). The C-terminal region of Bo3M(HVEII) contains a substitution of Lys for Arg at residue 231 and the motif DRG at the extreme C terminus, preceding the GPI cleavage site. It is not known whether one or another of these sequence differences is responsible for the observed difference in susceptibility to scrapie prions.
In Bo3M(HVEIV), a single additional change was made compared to Bo3M(HVEII): a substitution of Val for Ile at residue 226. Unexpectedly, the Tg(Bo3M,HVEIV) mice were completely resistant to BSE, vCJD, and scrapie prions. This is perplexing because this single change was designed to correct a mismatch in Bo3M(HVEII) with the binding motif of protein X, proposed to be required for the propagation of prions in murine cells (28) and Tg mice (29, 42, 62). All other residues in this motif are conserved between BoPrP and MoPrP. Contrary to expectation, all of the chimeric PrPs featuring Val at residue 226 were relatively resistant to all prion inocula, except for the Bo3M(YIQVV) construct (Table 2), which features an intact C-terminal MoPrP subdomain and two unchanged disulfide-linked helices. Tg mice expressing Bo3M(YIQVV) show complete resistance to scrapie prions, moderately short incubation periods with BSE prions (260 days), and short incubation times with vCJD prions (226 days), which is the shortest duration for vCJD prions in any Tg mouse line tested to date. No efficient Tg model for vCJD has yet been developed with human or chimeric human PrP transgenes (14, 29). It will be interesting to test whether a construct analogous to Bo3M(YIQVV) but containing Hu rather than Bo sequences confers enhanced susceptibility to vCJD or other strains of Hu prions.
Distinguishing BSE from scrapie prions in sheep. Three ORFs that we have tested in Tg mice feature Ile at both residues 214 and 226: Bo, Bo3M(HVEII), and Bo3M(YIQII). Mice expressing any one of the three constructs showed short incubation periods (230 days) when inoculated with BSE prions (Table 2). These data seem to indicate that preserving the sequence of helix B and at least part of helix C is desirable for the most efficient transmission of BSE prions. Mice expressing the Bo3M(YIQII) construct showed a substantial difference in susceptibility to BSE and scrapie prions, with incubation periods of 232 and 347 days, respectively, in the Tg(Bo3M,YIQII)23953 line, and 248 and 449 days, respectively, in Tg(Bo3M,YIQII)23939 mice (Table 2). Based on these differences, we selected the Tg(Bo3M,YIQII)23953 line for serial transmission studies and found that the incubation time for Tg(Bo3M,YIQII)-passaged BSE prions shortened from 232 to 170 days, whereas Tg(Bo3M,YIQII)-passaged scrapie prions showed a smaller decrease in the incubation period, from 347 to 313 days (Fig. 4). In light of concerns that BSE prions may have transmitted to sheep, Tg(Bo3M,YIQII) as well as the Tg(Bo3M,YIQVV) mice noted above may be of utility in screening sheep samples for the presence of BSE prions.
PrP amyloid deposition and florid plaques. BSE and vCJD prions caused similar neuropathologic phenotypes in Tg(BoPrP+/+)4092 and Tg(Bo3M,YIQII)23953 mice that were substantially different than those caused by scrapie prions (Fig. 5 and 6). These results agree with those we reported for transmission of BSE, vCJD, and scrapie prions in earlier studies with Tg(BoPrP) mice (58); unlike most established scrapie prion strains (6, 18, 19), BSE and vCJD prions are highly amyloidogenic (58). With respect to amyloid plaque formation, our present understanding is that an amyloidogenic conformation of an infecting PrPSc is imposed on the host's PrPC. Perhaps this amyloidogenic conformation favors natural truncation of PrPSc or presents surfaces that favor polymerization of PrPSc into amyloid filaments. Interestingly, the amyloid plaques formed in Tg(BoPrP+/+)4092 and Tg(Bo3M,YIQII)23953 mice resemble the florid plaques that are pathognomonic for vCJD in humans (66).
Earlier studies indicated that both the prion strain and the host genotype determine whether or not amyloid plaques form (6, 18, 19). Therefore, it is reasonable to hypothesize that the amino acid sequence of Bo3M(YIQII) expressed in Tg(Bo3M,YIQII)23953 mice enhances amyloid plaque formation, thereby causing the massive deposits of amyloid found from BSE and vCJD prions (Fig. 6A, B, E, and F).
Transgenes optimized for propagation of specific prion strains may provide faster and more efficient bioassays with animals, cultured cells, or cell-free systems. Unfortunately, it is not yet possible to predict whether a particular PrP sequence will confer susceptibility to any prion strain originating in a species with a different PrP sequence, although our work suggests that slight variations in or near all three helices of PrP can profoundly affect susceptibility in a strain-dependent manner. Our studies raise concerns that differences in the sequence of PrP may not be relied upon for protection from infection from prions of other species. Instead, susceptibility to prions appears to depend on both the sequence of PrP and the strain of prion, a conclusion that has serious implications for assessing the potential of prions to jump from one species, such as sheep or cattle, to another species, such as humans.
ACKNOWLEDGMENTS
This work was supported by grants from the National Institutes of Health (AG02132, AG10770, and AG021601) as well as by a gift from the G. Harold and Leila Y. Mathers Charitable Foundation.
We thank Pierre Lessard and the staff at the Hunters Point animal facility for support with the transgenic animal experiments, Jiri Safar for helpful discussions, Giuseppe Legname for antibodies, Hang Nguyen for expert editorial assistance, and Steve Feist for information technology support.
M.R.S., D.P., S.J.D., and S.B.P. have financial interest in InPro Biotechnology.
REFERENCES
Anderson, R. M., C. A. Donnelly, N. M. Ferguson, M. E. J. Woolhouse, C. J. Watt, H. J. Udy, S. MaWhinney, S. P. Dunstan, T. R. E. Southwood, J. W. Wilesmith, J. B. M. Ryan, L. J. Hoinville, J. E. Hillerton, A. R. Austin, and G. A. H. Wells. 1996. Transmission dynamics and epidemiology of BSE in British cattle. Nature 382:779-788.
Barlow, R. M., and J. C. Rennie. 1976. The fate of ME7 scrapie infection in rats, guinea-pigs and rabbits. Res. Vet. Sci. 21:110-111.
Barron, R. M., V. Thomson, E. Jamieson, D. W. Melton, J. Ironside, R. Will, and J. C. Manson. 2001. Changing a single amino acid in the N-terminus of murine PrP alters TSE incubation time across three species barriers. EMBO J. 20:5070-5078.
Basler, K., B. Oesch, M. Scott, D. Westaway, M. W?lchli, D. F. Groth, M. P. McKinley, S. B. Prusiner, and C. Weissmann. 1986. Scrapie and cellular PrP isoforms are encoded by the same chromosomal gene. Cell 46:417-428.
Bessen, R. A., and R. F. Marsh. 1994. Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy. J. Virol. 68:7859-7868.
Bruce, M. E., A. G. Dickinson, and H. Fraser. 1976. Cerebral amyloidosis in scrapie in the mouse: effect of agent strain and mouse genotype. Neuropathol. Appl. Neurobiol. 2:471-478.
Bruce, M. E., R. G. Will, J. W. Ironside, I. McConnell, D. Drummond, A. Suttie, L. McCardle, A. Chree, J. Hope, C. Birkett, S. Cousens, H. Fraser, and C. J. Bostock. 1997. Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent. Nature 389:498-501.
Buchanan, C. R., M. A. Preece, and R. D. G. Milner. 1991. Mortality, neoplasia and Creutzfeldt-Jakob disease in patients treated with pituitary growth hormone in the United Kingdom. Br. Med. J. 302:824-828.
Büeler, H., M. Fisher, Y. Lang, H. Bluethmann, H.-P. Lipp, S. J. DeArmond, S. B. Prusiner, M. Aguet, and C. Weissmann. 1992. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356:577-582.
Carlson, G. A., C. Ebeling, S.-L. Yang, G. Telling, M. Torchia, D. Groth, D. Westaway, S. J. DeArmond, and S. B. Prusiner. 1994. Prion isolate specified allotypic interactions between the cellular and scrapie prion proteins in congenic and transgenic mice. Proc. Natl. Acad. Sci. USA 91:5690-5694.
Carlson, G. A., P. A. Goodman, M. Lovett, B. A. Taylor, S. T. Marshall, M. Peterson-Torchia, D. Westaway, and S. B. Prusiner. 1988. Genetics and polymorphism of the mouse prion gene complex: control of scrapie incubation time. Mol. Cell. Biol. 8:5528-5540.
Caughey, B. W., A. Dong, K. S. Bhat, D. Ernst, S. F. Hayes, and W. S. Caughey. 1991. Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy. Biochemistry 30:7672-7680.
Chapman, J., J. Ben-Israel, Y. Goldhammer, and A. D. Korczyn. 1994. The risk of developing Creutzfeldt-Jakob disease in subjects with the PRNP gene codon 200 point mutation. Neurology 44:1683-1686.
Collinge, J., M. S. Palmer, K. C. Sidle, A. F. Hill, I. Gowland, J. Meads, E. Asante, R. Bradley, L. J. Doey, and P. L. Lantos. 1995. Unaltered susceptibility to BSE in transgenic mice expressing human prion protein. Nature 378:779-783.
Collinge, J., K. C. L. Sidle, J. Meads, J. Ironside, and A. F. Hill. 1996. Molecular analysis of prion strain variation and the aetiology of "new variant" CJD. Nature 383:685-690.
Cutlip, R. C., J. M. Miller, and H. D. Lehmkuhl. 1997. Second passage of a U.S. scrapie agent in cattle. J. Comp. Pathol. 117:271-275.
Ferguson, N. M., C. A. Donnelly, M. E. Woolhouse, and R. M. Anderson. 1997. The epidemiology of BSE in cattle herds in Great Britain. II. Model construction and analysis of transmission dynamics. Philos. Trans. R. Soc. Lond. B 352:803-838.
Fraser, H., and M. E. Bruce. 1973. Argyrophilic plaques in mice inoculated with scrapie from particular sources. Lancet i:617.
Fraser, H., and M. E. Bruce. 1983. Experimental control of cerebral amyloid in scrapie in mice, p. 281-290. In P. O. Behan, V. ter Meulen, and F. C. Rose (ed.), Immunology of nervous system infections. Progress in brain research, vol. 59. Elsevier Science Publishers, Amsterdam, The Netherlands.
Gibbs, C. J., Jr., and D. C. Gajdusek. 1973. Experimental subacute spongiform virus encephalopathies in primates and other laboratory animals. Science 182:67-68.
Gibbs, C. J., Jr., D. C. Gajdusek, D. M. Asher, M. P. Alpers, E. Beck, P. M. Daniel, and W. B. Matthews. 1968. Creutzfeldt-Jakob disease (spongiform encephalopathy): transmission to the chimpanzee. Science 161:388-389.
Goldgaber, D., L. G. Goldfarb, P. Brown, D. M. Asher, W. T. Brown, S. Lin, J. W. Teener, S. M. Feinstone, R. Rubenstein, R. J. Kascsak, J. W. Boellaard, and D. C. Gajdusek. 1989. Mutations in familial Creutzfeldt-Jakob disease and Gerstmann-Str?ussler-Scheinker's syndrome. Exp. Neurol. 106:204-206.
Hill, A. F., and J. Collinge. 2003. Subclinical prion infection in humans and animals. Br. Med. Bull. 66:161-170.
Hill, A. F., M. Desbruslais, S. Joiner, K. C. L. Sidle, I. Gowland, J. Collinge, L. J. Doey, and P. Lantos. 1997. The same prion strain causes vCJD and BSE. Nature 389:448-450.
Hill, A. F., S. Joiner, J. Linehan, M. Desbruslais, P. L. Lantos, and J. Collinge. 2000. Species-barrier-independent prion replication in apparently resistant species. Proc. Natl. Acad. Sci. USA 97:10248-10253.
Hope, J., L. Ritchie, C. Farquhar, R. Somerville, and N. Hunter. 1989. Bovine spongiform encephalopathy: a scrapie-like disease of British cattle. Prog. Clin. Biol. Res. 317:659-667.
Hsiao, K., Z. Meiner, E. Kahana, C. Cass, I. Kahana, D. Avrahami, G. Scarlato, O. Abramsky, S. B. Prusiner, and R. Gabizon. 1991. Mutation of the prion protein in Libyan Jews with Creutzfeldt-Jakob disease. N. Engl. J. Med. 324:1091-1097.
Kaneko, K., L. Zulianello, M. Scott, C. M. Cooper, A. C. Wallace, T. L. James, F. E. Cohen, and S. B. Prusiner. 1997. Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc. Natl. Acad. Sci. USA 94:10069-10074.
Korth, C., K. Kaneko, D. Groth, N. Heye, G. Telling, J. Mastrianni, P. Parchi, P. Gambetti, R. Will, J. Ironside, C. Heinrich, P. Tremblay, S. J. DeArmond, and S. B. Prusiner. 2003. Abbreviated incubation times for human prions in mice expressing a chimeric mouse-human prion protein transgene. Proc. Natl. Acad. Sci. USA 100:4784-4789.
Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
Lasmézas, C. I., J.-P. Deslys, R. Demaimay, K. T. Adjou, F. Lamoury, D. Dormont, O. Robain, J. Ironside, and J.-J. Hauw. 1996. BSE transmission to macaques. Nature 381:743-744.
Lasmézas, C. I., J.-P. Deslys, O. Robain, A. Jaegly, V. Beringue, J.-M. Peyrin, J.-G. Fournier, J.-J. Hauw, J. Rossier, and D. Dormont. 1997. Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. Science 275:402-405.
Liu, H., S. Farr-Jones, N. B. Ulyanov, M. Llinas, S. Marqusee, D. Groth, F. E. Cohen, S. B. Prusiner, and T. L. James. 1999. Solution structure of Syrian hamster prion protein rPrP(90-231). Biochemistry 38:5362-5377.
Manson, J. C., E. Jameison, H. Baybutt, N. L. Tuzi, R. Barron, I. McConnell, R. Somerville, J. Ironside, R. Will, M.-S. Sy, D. W. Melton, J. Hope, and C. Bostock. 1999. A single amino acid alteration (101L) introduced into murine PrP dramatically alters incubation time of transmissible spongiform encephalopathy. EMBO J. 18:6855-6864.
Muramoto, T., T. Kitamoto, J. Tateishi, and I. Goto. 1992. The sequential development of abnormal prion protein accumulation in mice with Creutzfeldt-Jakob disease. Am. J. Pathol. 140:1411-1420.
Nishida, N., D. A. Harris, D. Vilette, H. Laude, Y. Frobert, J. Grassi, D. Casanova, O. Milhavet, and S. Lehmann. 2000. Successful transmission of three mouse-adapted scrapie strains to murine neuroblastoma cell lines overexpressing wild-type mouse prion protein. J. Virol. 74:320-325.
Pan, K.-M., M. Baldwin, J. Nguyen, M. Gasset, A. Serban, D. Groth, I. Mehlhorn, Z. Huang, R. J. Fletterick, F. E. Cohen, and S. B. Prusiner. 1993. Conversion of -helices into ?-sheets features in the formation of the scrapie prion proteins. Proc. Natl. Acad. Sci. USA 90:10962-10966.
Pattison, I. H. 1965. Experiments with scrapie with special reference to the nature of the agent and the pathology of the disease, p. 249-257. In D. C. Gajdusek, C. J. Gibbs, Jr., and M. P. Alpers (ed.), Slow, latent and temperate virus infections. NINDB monograph 2. U.S. Government Printing Office, Washington, D.C.
Peretz, D., M. Scott, D. Groth, A. Williamson, D. Burton, F. E. Cohen, and S. B. Prusiner. 2001. Strain-specified relative conformational stability of the scrapie prion protein. Protein Sci. 10:854-863.
Peretz, D., R. A. Williamson, G. Legname, Y. Matsunaga, J. Vergara, D. Burton, S. J. DeArmond, S. B. Prusiner, and M. R. Scott. 2002. A change in the conformation of prions accompanies the emergence of a new prion strain. Neuron 34:921-932.
Peretz, D., R. A. Williamson, Y. Matsunaga, H. Serban, C. Pinilla, R. B. Bastidas, R. Rozenshteyn, T. L. James, R. A. Houghten, F. E. Cohen, S. B. Prusiner, and D. R. Burton. 1997. A conformational transition at the N-terminus of the prion protein features in formation of the scrapie isoform. J. Mol. Biol. 273:614-622.
Perrier, V., K. Kaneko, J. Safar, J. Vergara, P. Tremblay, S. J. DeArmond, F. E. Cohen, S. B. Prusiner, and A. C. Wallace. 2002. Dominant-negative inhibition of prion replication in transgenic mice. Proc. Natl. Acad. Sci. USA 99:13079-13084.
Prusiner, S. B. 1999. Development of the prion concept, p. 67-112. In S. B. Prusiner (ed.), Prion biology and diseases. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
Prusiner, S. B., D. Groth, A. Serban, R. Koehler, D. Foster, M. Torchia, D. Burton, S.-L. Yang, and S. J. DeArmond. 1993. Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc. Natl. Acad. Sci. USA 90:10608-10612.
Prusiner, S. B., D. F. Groth, D. C. Bolton, S. B. Kent, and L. E. Hood. 1984. Purification and structural studies of a major scrapie prion protein. Cell 38:127-134.
Prusiner, S. B., M. P. McKinley, K. A. Bowman, D. C. Bolton, P. E. Bendheim, D. F. Groth, and G. G. Glenner. 1983. Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 35:349-358.
Prusiner, S. B., M. Scott, D. Foster, K.-M. Pan, D. Groth, C. Mirenda, M. Torchia, S.-L. Yang, D. Serban, G. A. Carlson, P. C. Hoppe, D. Westaway, and S. J. DeArmond. 1990. Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication. Cell 63:673-686.
Race, R. E., S. A. Priola, R. A. Bessen, D. Ernst, J. Dockter, G. F. Rall, L. Mucke, B. Chesebro, and M. B. A. Oldstone. 1995. Neuron-specific expression of a hamster prion protein minigene in transgenic mice induces susceptibility to hamster scrapie agent. Neuron 15:1183-1191.
Riek, R., S. Hornemann, G. Wider, M. Billeter, R. Glockshuber, and K. Wüthrich. 1996. NMR structure of the mouse prion protein domain PrP(121-231). Nature 382:180-182.
Robinson, M. M., W. J. Hadlow, D. P. Knowles, T. P. Huff, P. A. Lacy, R. F. Marsh, and J. R. Gorham. 1995. Experimental infection of cattle with the agents of transmissible mink encephalopathy and scrapie. J. Comp. Pathol. 113:241-251.
Safar, J., P. P. Roller, D. C. Gajdusek, and C. J. Gibbs, Jr. 1993. Conformational transitions, dissociation, and unfolding of scrapie amyloid (prion) protein. J. Biol. Chem. 268:20276-20284.
Safar, J., H. Wille, V. Itri, D. Groth, H. Serban, M. Torchia, F. E. Cohen, and S. B. Prusiner. 1998. Eight prion strains have PrPSc molecules with different conformations. Nat. Med. 4:1157-1165.
Safar, J. G., M. Scott, J. Monaghan, C. Deering, S. Didorenko, J. Vergara, H. Ball, G. Legname, E. Leclerc, L. Solforosi, H. Serban, D. Groth, D. R. Burton, S. B. Prusiner, and R. A. Williamson. 2002. Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nat. Biotechnol. 20:1147-1150.
Scott, M., D. Foster, C. Mirenda, D. Serban, F. Coufal, M. W?lchli, M. Torchia, D. Groth, G. Carlson, S. J. DeArmond, D. Westaway, and S. B. Prusiner. 1989. Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques. Cell 59:847-857.
Scott, M., D. Groth, D. Foster, M. Torchia, S.-L. Yang, S. J. DeArmond, and S. B. Prusiner. 1993. Propagation of prions with artificial properties in transgenic mice expressing chimeric PrP genes. Cell 73:979-988.
Scott, M. R., R. K?hler, D. Foster, and S. B. Prusiner. 1992. Chimeric prion protein expression in cultured cells and transgenic mice. Protein Sci. 1:986-997.
Scott, M. R., J. Safar, G. Telling, O. Nguyen, D. Groth, M. Torchia, R. Koehler, P. Tremblay, D. Walther, F. E. Cohen, S. J. DeArmond, and S. B. Prusiner. 1997. Identification of a prion protein epitope modulating transmission of bovine spongiform encephalopathy prions to transgenic mice. Proc. Natl. Acad. Sci. USA 94:14279-14284.
Scott, M. R., R. Will, J. Ironside, H.-O. B. Nguyen, P. Tremblay, S. J. DeArmond, and S. B. Prusiner. 1999. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc. Natl. Acad. Sci. USA 96:15137-15142.
Spudich, S., J. A. Mastrianni, M. Wrensch, R. Gabizon, Z. Meiner, I. Kahana, H. Rosenmann, E. Kahana, and S. B. Prusiner. 1995. Complete penetrance of Creutzfeldt-Jakob disease in Libyan Jews carrying the E200K mutation in the prion protein gene. Mol. Med. 1:607-613.
Supattapone, S., P. Bosque, T. Muramoto, H. Wille, C. Aagaard, D. Peretz, H.-O. B. Nguyen, C. Heinrich, M. Torchia, J. Safar, F. E. Cohen, S. J. DeArmond, S. B. Prusiner, and M. Scott. 1999. Prion protein of 106 residues creates an artificial transmission barrier for prion replication in transgenic mice. Cell 96:869-878.
Telling, G. C., P. Parchi, S. J. DeArmond, P. Cortelli, P. Montagna, R. Gabizon, J. Mastrianni, E. Lugaresi, P. Gambetti, and S. B. Prusiner. 1996. Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science 274:2079-2082.
Telling, G. C., M. Scott, J. Mastrianni, R. Gabizon, M. Torchia, F. E. Cohen, S. J. DeArmond, and S. B. Prusiner. 1995. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell 83:79-90.
Tremblay, P., Z. Meiner, M. Galou, C. Heinrich, C. Petromilli, T. Lisse, J. Cayetano, M. Torchia, W. Mobley, H. Bujard, S. J. DeArmond, and S. B. Prusiner. 1998. Doxycyline control of prion protein transgene expression modulates prion disease in mice. Proc. Natl. Acad. Sci. USA 95:12580-12585.
Westaway, D., V. Zuliani, C. M. Cooper, M. Da Costa, S. Neuman, A. L. Jenny, L. Detwiler, and S. B. Prusiner. 1994. Homozygosity for prion protein alleles encoding glutamine-171 renders sheep susceptible to natural scrapie. Genes Dev. 8:959-969.
Will, R. G., S. N. Cousens, C. P. Farrington, P. G. Smith, R. S. G. Knight, and J. W. Ironside. 1999. Deaths from variant Creutzfeldt-Jakob disease. Lancet 353:979.
Will, R. G., J. W. Ironside, M. Zeidler, S. N. Cousens, K. Estibeiro, A. Alperovitch, S. Poser, M. Pocchiari, A. Hofman, and P. G. Smith. 1996. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347:921-925.
Wille, H., M. D. Michelitsch, V. Guénebaut, S. Supattapone, A. Serban, F. E. Cohen, D. A. Agard, and S. B. Prusiner. 2002. Structural studies of the scrapie prion protein by electron crystallography. Proc. Natl. Acad. Sci. USA 99:3563-3568.
Williams, E. S., and S. Young. 1982. Spongiform encephalopathy of Rocky Mountain Elk. J. Wildl. Dis. 18:465-471.(Michael R. Scott, David P)